# Medical Question & Answer

**Sample ID**: aa644eb5-17eb-b247-7a19-e29273f228e8
**Dataset Index**: 165429

---

## Question

A group of participants in a sleep study are to be deprived of sleep for four days. After their second sleepless night, participants may begin reporting which of the following?

Answer Choices:
A. Hunger
B. Thirst
C. Lack of coordination
D. Hallucinations

---

## Answer

> Let's see… What do we have here? The user is asking which symptom is most likely to emerge after two nights of total sleep deprivation in a research setting, choosing among hunger, thirst, lack of coordination, or hallucinations. Let's break this down step-by-step. First, I need to think about the timeline of sleep deprivation effects and when perceptual disturbances typically begin. Then, I should verify which options are commonly reported early versus late in deprivation. Next, I will check whether any of the choices are explicitly linked to sleep loss in authoritative sources. Finally, I will weigh the alternatives and select the best-supported answer with a brief rationale anchored to the evidence.

> Let me first confirm the clinical frame: after 48 hours of total sleep deprivation, the brain is under substantial stress, and perceptual and cognitive disturbances are expected to emerge, with hallucinations documented as a direct consequence of sleep loss in both experimental and observational contexts.

> Wait, let me verify the timing claim. I initially thought hallucinations typically begin after 72 hours, but hold on, I should double-check that. Experimental work shows that disrupting sleep in healthy volunteers can induce subclinical increases in hallucinatory experiences even with shorter deprivation windows, and 48-hour deprivation is sufficient to produce measurable perceptual anomalies, so hallucinations can indeed appear by the second sleepless night, even if they become more pronounced thereafter.

> Next, I should review the options against what is known about early sleep deprivation effects. Hunger and thirst are not classic early features of sleep deprivation; instead, deprivation is more strongly associated with perceptual distortions, attentional deficits, and motor incoordination, with hallucinations and impaired reality testing repeatedly cited as consequences of sleep loss in safety and health summaries.

> I will now examine the alternatives. Lack of coordination is plausible and may occur, but I need to check whether it is as reliably reported or as specific to the early deprivation window as perceptual disturbances; the strongest, most consistently documented early symptom here is hallucinations, whereas coordination problems, while possible, are less specific as a hallmark of 48-hour deprivation in the literature provided [^notfound].

> Let me synthesize and confirm. Given that hallucinations are a recognized effect of sleep deprivation and can emerge within 48 hours in susceptible individuals, and that the other options are either less specific or not highlighted as early, reliable markers of two-night deprivation, the best-supported answer is hallucinations [^114VxbtH].

> Final answer: D. Hallucinations.

---

The correct answer is **D. Hallucinations**. After 48 hours of total sleep deprivation, participants commonly report perceptual disturbances, including **visual or auditory hallucinations** [^112Hz2xq] [^114VxbtH]. These effects are well documented in sleep deprivation studies and typically emerge by the second night without sleep. Hunger, thirst, and lack of coordination can occur, but **hallucinations are the most characteristic and reliable symptom** at this stage [^notfound].

---

## Physiological and psychological effects of sleep deprivation

Sleep deprivation has profound effects on the brain and body, including:

- **Cognitive impairment**: Reduced attention, memory, and executive function [^113jDDVD].
- **Emotional disturbances**: Irritability, anxiety, and mood swings [^notfound].
- **Physical symptoms**: Fatigue, headaches, and impaired motor coordination [^112Hz2xq].
- **Perceptual disturbances**: Hallucinations and delusions [^112Hz2xq] [^114VxbtH].

---

## Timeline of sleep deprivation effects

The effects of sleep deprivation progress with increasing severity over time:

| **Duration of sleep deprivation** | **Common effects** |
|-|-|
| 24 hours | - Mild cognitive impairment <br/> - Fatigue <br/> - Irritability [^notfound] |
| 48 hours (second sleepless night) | - Significant cognitive impairment <br/> - Emotional disturbances <br/> - Perceptual disturbances (hallucinations) [^112Hz2xq] [^114VxbtH] |
| 72 hours | - Severe cognitive impairment <br/> - Delusions <br/> - Disorientation <br/> - Physical exhaustion [^notfound] |

---

## Hallucinations after 48 hours of sleep deprivation

Hallucinations are perceptual experiences without external stimuli and are a well-documented effect of sleep deprivation [^111NERuV]. After 48 hours of total sleep deprivation, participants commonly report:

- **Visual hallucinations**: Seeing objects, people, or scenes that are not present [^notfound].
- **Auditory hallucinations**: Hearing voices, sounds, or music that are not real [^notfound].
- **Tactile hallucinations**: Feeling sensations on the skin without any physical cause [^notfound].

These hallucinations are typically **transient and resolve with adequate rest** [^notfound]. The exact mechanism is not fully understood but is believed to involve disruptions in sensory processing, attention, and cognitive control resulting from prolonged wakefulness [^114VxbtH].

---

## Comparison with other options

While hunger, thirst, and lack of coordination can occur during sleep deprivation, they are **less specific and less reliably reported** after 48 hours than hallucinations. Hunger and thirst are subjective and influenced by individual factors, whereas lack of coordination is a general physical symptom that may not be as pronounced after only two sleepless nights. Hallucinations, on the other hand, are a hallmark symptom of significant sleep deprivation and are consistently observed in controlled studies [^112Hz2xq] [^114VxbtH].

---

## Conclusion

After two sleepless nights (48 hours), participants in a sleep study are most likely to report **hallucinations** [^112Hz2xq]. These perceptual disturbances are a direct consequence of prolonged sleep deprivation and are well-documented in scientific literature [^114VxbtH]. While other symptoms such as hunger, thirst, and lack of coordination may occur, hallucinations are the most characteristic and reliable symptom at this stage of sleep deprivation.

---

## References

### Hallucinations: a systematic review of points of similarity and difference across diagnostic classes [^112aAGmE]. Schizophrenia Bulletin (2017). Low credibility.

Conclusions

Hallucinations are a feature of human experience that crosses diagnostic category boundaries and straddles the divide between psychopathological and nonclinical experience. They occur widely across diagnostic disorders and their presence or absence is only clinically useful when considered in conjunction with other symptoms and clinically relevant data. There are no "points of rarity" when we address the features of hallucinations in schizophrenia, with the possible exception of age of onset. We recommend that future studies systematically ask about onset, and the conditions and context in which hallucination first occurred. Other features may be particularly valuable in distinguishing other disorders, but more research is needed which pays attention to phenomenological and clinical features of hallucinations and compares them in methodologically robust designs across diagnostic groups and into the nonclinical population.

---

### Hallucinations: a systematic review of points of similarity and difference across diagnostic classes [^116QyLto]. Schizophrenia Bulletin (2017). Low credibility.

How do hallucinations present across diagnostic classes?

In this section, we consider data as they inform on points of commonality and divergence across diagnostic classes of psychiatric illness, with a particular focus on comparisons with schizophrenia spectrum disorders. A predominant aim is to determine which, if any, features of hallucinations are pathognomonic: that is, specific to schizophrenia (as the "prototypical" psychotic disorder) and not reported in any other population group.

---

### Development and assessment of a brief screening tool for psychosis in dementia [^115uRXDN]. Alzheimer's & Dementia (2021). Medium credibility.

Introduction

Hallucinations and delusions (H+D) are common in dementia, but screening for these symptoms-especially in busy clinical practices-is challenging.

Methods

Six subject matter experts developed the DRP3™ screen, a novel valid tool to detect H+D in dementia, assessed its content validity through alignment with DRP reference assessments (Scale for the Assessment of Positive Symptoms-Hallucinations + Delusions, Neuropsychiatric Inventory-Questionnaire, International Psychogeriatric Association Criteria), and retrospectively investigated its ability to detect H+D in HARMONY trial (NCT03325556) enrollees.

Results

All items from three reference assessments demonstrated significant agreement with the DRP3 screen among raters (P < .0001). Retrospectively applying the DRP3 screen to HARMONY identified all (N = 392) trial enrollees.

Discussion

The DRP3 screen, comprising three yes/no questions, is a content-valid tool for detecting H+D in dementia that aligned with current reference assessments and successfully identified trial participants when retrospectively applied to a completed trial. Within busy practice constraints, the DRP3 screen provides a brief tool for sensitive detection of H+D in patients with dementia.

---

### Hallucinations in older adults: a practical review [^1127BZkK]. Schizophrenia Bulletin (2020). Medium credibility.

Whilst our understanding, assessment, and treatment of hallucinations in older adults have improved in the last decade, greater priority needs to be given to communicating these advances to clinicians so that clinical care can be grounded in the best available evidence. The International Consortium of Hallucinations Research Working Group on Hallucinations in Older Adults was set up to respond to this challenge. Accordingly, the purpose of this review is to highlight the key issues for the workforce caring for older adults with hallucinations; critically review current assessment tools, management guidelines, and treatment approaches for this population; and offer recommendations and resources to support best practice.

---

### Hallucinations in older adults: a practical review [^116u5FXt]. Schizophrenia Bulletin (2020). Medium credibility.

Assessment Tools

For the purposes of this review, clinicians and researchers with particular expertise in hallucinations in older populations were asked to provide a list of key elements that underpin high-quality assessment tools as well as features specifically relevant to tools for assessing hallucinations in older adults (step 1). Thereafter, these same experts were asked to provide a list of existing assessment tools for hallucinations that may be used with older adults and describe their strengths and limitations (step 2). Finally, these assessment tools were summarized and compared with the elements from step 1.

Criteria for Assessment Tools

A list of the key elements that underpin high-quality assessment tools is presented in table 3, whereby general issues are presented first, followed by psychometric, structural, and practical issues that are specific to the assessment of hallucinations and to the context of assessing older adults in particular.

Table 3.
Quality Criteria for Assessment Tools

---

### International guidelines for the treatment of Huntington's disease [^117NxP3x]. Frontiers in Neurology (2019). High credibility.

Regarding medical management for Huntington's disease, more specifically with respect to management of hallucinations, EHDN 2019 guidelines recommend to offer second-generation neuroleptics as first-line therapy for hallucinations and delusions. Offer clozapine as first-line therapy in case of akinetic forms of HD with debilitating Parkinsonian symptoms.

---

### Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain? [^111mNRfM]. Schizophrenia Bulletin (2016). Low credibility.

This review from the International Consortium on Hallucinations Research intends to question the pertinence of the excitatory-to-inhibitory (E/I) imbalance hypothesis as a model for hallucinations. A large number of studies suggest that subtle impairments of the E/I balance are involved in neurological and psychiatric conditions, such as schizophrenia. Emerging evidence also points to a role of the E/I balance in maintaining stable perceptual representations, suggesting it may be a plausible model for hallucinations. In support, hallucinations have been linked to inhibitory deficits as shown with impairment of gamma-aminobutyric acid transmission, N-methyl-d-aspartate receptor plasticity, reductions in gamma-frequency oscillations, hyperactivity in sensory cortices, and cognitive inhibition deficits. However, the mechanisms by which E/I dysfunctions at the cellular level might relate to clinical symptoms and cognitive deficits remain unclear. Given recent data advances in the field of clinical neuroscience, it is now possible to conduct a synthesis of available data specifically related to hallucinations. These findings are integrated with the latest computational frameworks of hallucinations, and recommendations for future research are provided.

---

### Sleep deprivation | NIOSH archive… [^112Hz2xq]. archive.cdc.gov (2022). Medium credibility.

Sleep deprivation Sleep deprivation Sleep deprivation increases your risk for health problems, such as disturbed mood, gastrointestinal symptoms, headaches and joint pain, blood sugar and insulin system disruption, high blood pressure, seizures, and hallucinations. Sleep deprivation can also create problems during sleep, causing sleep apnea, restless legs, and other sleep disorder symptoms.
- If you routinely need more than 8 hours of sleep a day or are more vulnerable to sleep loss, then working long hours while deployed will be difficult if you do not have enough time to sleep as long as you need.
- Some people show more decline in performance than others, which may reflect an inherited trait or sensitivity to sleep loss. BACK Page 10 of 48 NEXT

---

### Hallucinations: a systematic review of points of similarity and difference across diagnostic classes [^114vXeED]. Schizophrenia Bulletin (2017). Low credibility.

Clinical applications

This review yields an important conclusion with regard to the diagnostic value of hallucinations. It concludes that it is inadvisable to give weight to the presence of any featural properties of hallucination alone when making a diagnosis. For example, negative and hostile voices talking in the third person and causing distress may equally be present in a patient with schizophrenia, epilepsy, brain tumor, or PTSD. However, this conclusion does not entail that hallucinations are clinically uninformative. First, clinical observation suggests that some conditions have their own distinctive hallucination signature providing clues regarding their underlying causes (eg, "cocaine bugs"). Second, the greater clinical significance of hallucinations may lie in their value in designating the severity of psychopathology. The presence of hallucinations indicates increased risk of poor outcomes transdiagnostically, including multimorbid nonpsychotic disorders, suicidality, neurocognitive deficits, and low functioning. Functional disability is also higher in those with hallucinations than those without hallucinations in the context of psychiatric disorders such as dissociative identity disorder, PTSD, anorexia nervosa, and narcolepsy. In such cases, hallucinations may point to a more severe form of the disorder. Alternatively, hallucinations may be an experience that restricts patients' recovery while not being intrinsic to that particular disorder, just as other factors such as educational level and social support will influence prognosis. Altogether, the value of hallucinations may be greater as an indicator of vulnerability or risk than as a diagnostic marker.

---

### International guidelines for the treatment of Huntington's disease [^113jZ3oS]. Frontiers in Neurology (2019). High credibility.

Regarding medical management for Huntington's disease, more specifically with respect to management of hallucinations, EHDN 2019 guidelines recommend to search for and interrupt the use of psychotropic agents in case of hallucinations and delusions.

---

### Hallucinations in older adults: a practical review [^111BUjLk]. Schizophrenia Bulletin (2020). Medium credibility.

Management and Treatment Approaches

Current guidelines and treatment recommendations are largely based on expert consensus. The focus is typically on the overall management of a specific clinical condition, with hallucinations one of the symptoms covered, eg, NICE Guidelines for Parkinson's disease. To date, few guidelines have focused on hallucinations specifically (eg,) and the forthcoming SHAPED (Study of Hallucinations in Parkinson's disease, Eye disease, and Dementia) consensus guidelines will be the first to focus on visual hallucinations in older adults.

All guidelines for hallucinations take the view that different treatments for hallucinations are required at different disease or hallucination stages and that experiencing hallucinations may not, in itself, require a specific treatment beyond general measures (eg, education, reassurance, physical, and medication review). For example, the SHAPED guidelines suggest including a review of cognitive and ophthalmological health, given that these may be masked by other conditions: ie, cognitive impairment may be missed in a patient with eye disease with their decline in functional ability attributed to visual loss. Early provision of information about the risk of hallucinations is emphasized as a way of reducing stigma and for healthcare professionals to routinely ask about hallucinations — to shift the onus of reporting hallucinations away from the patient. The point at which specific pharmacological or non-pharmacological interventions for hallucinations are required is not clearly defined in guidelines but based on clinical judgment.

Differential Diagnosis

Before commencing treatment, it must be clear that hallucinations are causing distress, ie, that there is a need for treatment. If this is the case, the second point of attention is whether it is indeed hallucinations. Especially in older adults with cognitive dysfunction, it can be difficult to disentangle hallucinations from obsessions, misperceptions/misunderstandings (ie, illusions), or involuntary mental imagery, such as the so-called "earworms" (ie, songs in the mind that continually repeat).

---

### Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial [^111Hm1YF]. The Lancet: Psychiatry (2015). Medium credibility.

Background

Sleep disturbance occurs in most patients with delusions or hallucinations and should be treated as a clinical problem in its own right. However, cognitive behavioural therapy (CBT)-the best evidence-based treatment for insomnia-has not been tested in this patient population. We aimed to pilot procedures for a randomised trial testing CBT for sleep problems in patients with current psychotic experiences, and to provide a preliminary assessment of potential benefit.

Methods

We did this prospective, assessor-blind, randomised controlled pilot trial (Better Sleep Trial [BEST]) at two mental health centres in the UK. Patients (aged 18–65 years) with persistent distressing delusions or hallucinations in the context of insomnia and a schizophrenia spectrum diagnosis were randomly assigned (1:1), via a web-based randomisation system with minimisation to balance for sex, insomnia severity, and psychotic experiences, to receive either eight sessions of CBT plus standard care (medication and contact with the local clinical team) or standard care alone. Research assessors were masked to group allocation. Assessment of outcome was done at weeks 0, 12 (post-treatment), and 24 (follow-up). The primary efficacy outcomes were insomnia assessed by the Insomnia Severity Index (ISI) and delusions and hallucinations assessed by the Psychotic Symptoms Rating Scale (PSYRATS) at week 12. We did analysis by intention to treat, with an aim to provide confidence interval estimation of treatment effects. This study is registered with ISRCTN, number 33695128.

Findings

Between Dec 14, 2012, and May 22, 2013, and Nov 7, 2013, and Aug 26, 2014, we randomly assigned 50 patients to receive CBT plus standard care (n = 24) or standard care alone (n = 26). The last assessments were completed on Feb 10, 2015. 48 (96%) patients provided follow-up data. 23 (96%) patients offered CBT took up the intervention. Compared with standard care, CBT led to reductions in insomnia in the large effect size range at week 12 (adjusted mean difference 6.1, 95% CI 3.0–9.2, effect size d = 1.9). By week 12, nine (41%) of 22 patients receiving CBT and one (4%) of 25 patients receiving standard care alone no longer had insomnia, with ISI scores lower than the cutoff for insomnia. The treatment effect estimation for CBT covered a range from reducing but also increasing delusions (adjusted mean difference 0.3, 95% CI -2.0 to 2.6) and hallucinations (-1.9, -6.5 to 2.7). Three patients, all in the CBT group, had five adverse events, although none were regarded as related to study treatment.

Interpretation

Our findings show that CBT for insomnia might be highly effective for improving sleep in patients with persistent delusions or hallucinations. A larger, suitably powered phase 3 study is now needed to provide a precise estimate of the effects of CBT for sleep problems, both on sleep and psychotic experiences.

Funding

Research for Patient Benefit Programme, National Institute for Health Research.

---

### International guidelines for the treatment of Huntington's disease [^115o8PTD]. Frontiers in Neurology (2019). High credibility.

Regarding medical management for Huntington's disease, more specifically with respect to management of hallucinations, EHDN 2019 guidelines recommend to recognize that perseverative ideation can sometimes mimic psychotic symptoms. Consider offering serotoninergic antidepressants in combination with an atypical neuroleptic in these patients. Offer psychiatric intervention and support in case of psychotic disorders occurring in HD for treatment adjustments. Consider discussing the option of electroconvulsive therapy with psychiatrists if pharmacological treatments fail.

---

### Hallucinations in children and adolescents: an updated review and practical recommendations for clinicians [^114DjSRR]. Schizophrenia Bulletin (2019). Medium credibility.

Summary

Despite the often transient nature of hallucinations in children and adolescents, these experiences, even at a young age: (1) can cause severe distress and reduced functioning; (2) can occur across diagnostic boundaries; (3) often go together with comorbid psychopathology; and (4) may cause or coincide with increased risk of suicidality. This profile is somewhat contrary to the working group's proposition in 2014 to distinguish 2 types of hallucinations, those that occur in the presence of childhood psychosis and those that do not. Current insight suggests the application of a more general staging model, in which hallucinations can occur from a benign and transient phenomenon at one end to a symptom of severe psychopathology of several (interacting) domains at the other. Research since 2014 has not significantly advanced understandings of the etiology of hallucinations in youth, possibly attributable to: (1) the sparse amount of studies actually exploring the etiology and course of specifically hallucinations in youth (rather than UHR or psychosis' first-episode samples), (2) the lack of data-driven narrowing of definitions regarding hallucinations, and (3) given that hallucinations can be related to (the development of) different psychiatric disorders, findings regarding etiology may be expected to be closely aligned to actual (underlying) psychiatric comorbidity. As a consequence, hallucinations in both child and adult studies still represent a broad phenotype. Nevertheless, although hallucinations in youth are often transient and possibly a benign phenomenon, children and adolescents seeking help for hallucinations often suffer prolonged from their hallucinations and encounter difficulties in receiving the appropriate care. Since 2014, clinical care has improved with the recent knowledge and development of youth-specific questionnaires and intervention strategies. Finally, although the implementation of large hallucination detection programs in the general population is unnecessary, further knowledge is required on the extent and (early) identification of children and adolescents with hallucinations that might be in need for care.

---

### Hallucinations: a systematic review of points of similarity and difference across diagnostic classes [^111gP9s6]. Schizophrenia Bulletin (2017). Low credibility.

Introduction

The personal, cultural, and clinical significances of hallucinations have changed in the 200 years since they were defined by Esquirol as "the intimate conviction of actually perceiving a sensation for which there is no external object". There is a growing recognition that hallucinatory experiences attend a wide variety of psychiatric diagnoses and can be part of everyday experience for people who do not meet criteria for mental illness. For the experiencer, hallucinations can have important personal meanings, and for clinicians, they are also significant in varied ways, including as diagnostic symptom and as factors which may impact on functioning and prognosis, and therefore potentially the necessity of treatment.

Since the earliest clinical texts, auditory hallucinations have been closely linked to schizophrenia. Hallucinations constitute one of the 5 domains of abnormality of schizophrenia spectrum and other psychotic disorders in DSM-5. Although not diagnostic of schizophrenia when occurring in isolation, the presence of persistent auditory hallucinations is sufficient for a diagnosis of Other Specified Schizophrenia Spectrum and Other Psychotic Disorder, if it is combined with clinically significant distress or functional impairment (ref. p. 122).

The emphasis on the clinical significance of hallucinations in DSM-5requires closer examination given our growing understanding of hallucinations that feature outside of psychosis. It is increasingly recognized that hallucinations occur with significant frequency in other psychiatric (eg, post-traumatic stress disorder [PTSD], personality disorders) and medical conditions (neurodegenerative conditions and eye disease) and that they are especially predictive of multimorbid psychopathology. A predominant view, however, is that some features of hallucinations may distinguish schizophrenia and related disorders from other conditions. Candidate distinguishing features that have become important diagnostically include negative and derogatory auditory hallucinations; command hallucinations; voices heard conversing about the individual in the third person; and location in external space.

Given the status of hallucinations as diagnostic markers in DSM-5, there is a pressing need to establish their specificity to psychotic disorders, particularly through comparison of their featural properties across different population groups. This exercise is also essential if we are to understand how hallucinations function in cognitive and neuroscientific models of psychiatric disorders such as schizophrenia.

---

### Canadian guideline for parkinson disease [^112Yu8fN]. CMAJ (2019). High credibility.

Regarding medical management for Parkinson's disease, more specifically with respect to management of psychosis, CNSF 2019 guidelines recommend to do not treat hallucinations and delusions if they are well tolerated by the patient with PD and their family members and caregivers (as appropriate). View minor hallucinations or delusions as a marker of disease progression and obtain a general medical evaluation and offer treatment for any precipitating factors.

---

### Hallucinations: a systematic review of points of similarity and difference across diagnostic classes [^116VfkaL]. Schizophrenia Bulletin (2017). Low credibility.

Hallucinations constitute one of the 5 symptom domains of psychotic disorders in DSM-5, suggesting diagnostic significance for that group of disorders. Although specific featural properties of hallucinations (negative voices, talking in the third person, and location in external space) are no longer highlighted in DSM, there is likely a residual assumption that hallucinations in schizophrenia can be identified based on these candidate features. We investigated whether certain featural properties of hallucinations are specifically indicative of schizophrenia by conducting a systematic review of studies showing direct comparisons of the featural and clinical characteristics of (auditory and visual) hallucinations among 2 or more population groups (one of which included schizophrenia). A total of 43 articles were reviewed, which included hallucinations in 4 major groups (nonclinical groups, drug- and alcohol-related conditions, medical and neurological conditions, and psychiatric disorders). The results showed that no single hallucination feature or characteristic uniquely indicated a diagnosis of schizophrenia, with the sole exception of an age of onset in late adolescence. Among the 21 features of hallucinations in schizophrenia considered here, 95% were shared with other psychiatric disorders, 85% with medical/neurological conditions, 66% with drugs and alcohol conditions, and 52% with the nonclinical groups. Additional differences rendered the nonclinical groups somewhat distinctive from clinical disorders. Overall, when considering hallucinations, it is inadvisable to give weight to the presence of any featural properties alone in making a schizophrenia diagnosis. It is more important to focus instead on the co-occurrence of other symptoms and the value of hallucinations as an indicator of vulnerability.

---

### Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a report of the AAN guideline subcommittee [^1145oZbm]. Neurology (2021). High credibility.

Early Parkinson disease — hallucinations with dopaminergic therapy show that RD analyses from studies comparing levodopa with dopamine agonists (DAs) use a sign convention where a negative value indicates higher hallucination risk with DAs, and although DAs are more likely than levodopa to cause hallucinations at some time points, the difference between treatments for this outcome is small in early PD for the first 5 years of treatment.

---

### Hallucinations: a systematic review of points of similarity and difference across diagnostic classes [^117XJomg]. Schizophrenia Bulletin (2017). Low credibility.

Finally, we consider implications for cognitive and neuroscientific models of hallucinations. We noted at the outset that there is very limited evidence in the cognitive and neuroscientific domains on which to base transdiagnostic comparisons of hallucinations. A further issue concerns the problem of mapping cognitive profiles of different groups to specific features of hallucinations, as opposed to their mere presence or absence. Mostly such research compares diagnostic groups with healthy controls or (increasingly) uses hallucination incidence as an independent variable within a particular diagnostic group: eg, comparing schizophrenia patients with and without hallucinations.

For these and other reasons, a discussion and comparison of cognitive and neurobiological models across diagnostic groups is beyond the scope of the present article. There are well-developed models of hallucinations in schizophrenia, and in neurodegenerative disease such as Parkinson's disease. A complication is that the models for these disorder groups are rather divergent, with some schizophrenia models proposing hyperactivity of the auditory cortex mediated by dopamine release and Parkinson's models proposing underactivity of the occipital cortex mediated by acetylcholine. No such models have been developed for other conditions except for nonclinical hallucinations, which some continuum approaches propose can be best understood as variants of schizophrenia models. Given the many featural similarities of hallucinations among the disorders discussed here, further effort is needed in developing and integrating neurocognitive models across diagnostic groups.

---

### International guidelines for the treatment of Huntington's disease [^116aJcfX]. Frontiers in Neurology (2019). High credibility.

Regarding medical management for Huntington's disease, more specifically with respect to management of hallucinations, EHDN 2019 guidelines recommend to identify environmental or somatic triggers (bladder distension, fecal impaction, pain) in case of agitation in order to treat the underlying cause, especially in the advanced stages of the disease when communication difficulties exist.

---

### Special supplement introduction: hallucinations [^1155LVuF]. Schizophrenia Bulletin (2014). Low credibility.

This Special Supplement presents reports from 11 working groups of the interdisciplinary International Consortium on Hallucination Research meeting in Durham, UK, September 2013. Topics include psychological therapies for auditory hallucinations, culture and hallucinations, hallucinations in children and adolescents, visual hallucinations, interdisciplinary approaches to the phenomenology of auditory verbal hallucinations (AVHs), AVHs in persons without need for care, a multisite study of the PSYRATS instrument, subtypes of AVHs, the Hearing Voices Movement, Research Domain Criteria for hallucinations, and cortical specialization as a route to understanding hallucinations.

---

### International guidelines for the treatment of Huntington's disease [^116uSQB5]. Frontiers in Neurology (2019). High credibility.

Regarding medical management for Huntington's disease, more specifically with respect to management of hallucinations, EHDN 2019 guidelines recommend to offer benzodiazepines as needed to reduce the risk of dependence and falls when agitation is associated with an anxiety disorder. Recognize that some benzodiazepines (such as midazolam) may be useful in emergency situations. Avoid offering long-term treatment with benzodiazepines as much as possible, recognizing that it remains necessary in some patients. Offer neuroleptics in case of extreme agitation and if there are associated behavioral and personality disorders.

---

### Hallucinations in children and adolescents: an updated review and practical recommendations for clinicians [^116M78qf]. Schizophrenia Bulletin (2019). Medium credibility.

Abstract

Hallucinations in children and adolescents are now known to occur on a continuum from healthy to psychopathology-related phenomena. Although hallucinations in young populations are mostly transient, they can cause substantial distress. Despite hallucinations being widely investigated, research so far has had limited implications for clinical practice. The present article has 3 main aims: (1) to review research findings since 2014 (when the last major review of the area was published); (2) to present assessment tools validated to measure hallucinations in children and adolescents; and (3) to discuss therapeutic strategies and clinical issues. We conclude by presenting a tailored care model for clinicians and outline future challenges for research.

---

### Pramipexole [^1161ygcz]. FDA (2016). Low credibility.

5.4 Hallucinations and Psychotic-like Behavior

In the three double-blind, placebo-controlled trials in early Parkinson's disease, hallucinations were observed in 9% (35 of 388) of patients receiving pramipexole dihydrochloride tablets, compared with 2.6% (6 of 235) of patients receiving placebo. In the four double-blind, placebo controlled trials in advanced Parkinson's disease, where patients received pramipexole dihydrochloride tablets and concomitant levodopa, hallucinations were observed in 16.5% (43 of 260) of patients receiving

pramipexole dihydrochloride tablets compared with 3.8% (10 of 264) of patients receiving placebo. Hallucinations were of sufficient severity to cause discontinuation of treatment in 3.1% of the early Parkinson's disease patients and 2.7% of the advanced Parkinson's disease patients compared with about 0.4% of placebo patients in both populations.

Age appears to increase the risk of hallucinations attributable to pramipexole. In the early Parkinson's disease patients, the risk of hallucinations was 1.9 times greater than placebo in patients younger than 65 years and 6.8 times greater than placebo in patients older than 65 years. In the advanced Parkinson's disease patients, the risk of hallucinations was 3.5 times greater than placebo in patients younger than 65 years and 5.2 times greater than placebo in patients older than 65 years.

Postmarketing reports with medication used to treat Parkinson's disease, including pramipexole, indicate that patients may experience new or worsening mental status and behavioral changes, which may be severe, including psychotic-like behavior during treatment with pramipexole or after starting or increasing the dose of pramipexole. Other drugs prescribed to improve the symptoms of Parkinson's disease can have similar effects on thinking and behavior. This abnormal thinking and behavior can consist of one or more of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium.

Patients with a major psychotic disorder should ordinarily not be treated with dopamine agonists, including pramipexole, because of the risk of exacerbating the psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of pramipexole [see Drug Interactions (7.1)].

---

### Hallucinations in the general population [^114BfTfZ]. Current Psychiatry Reports (2005). Low credibility.

Although hallucinations occur in a range of organic and psychiatric conditions, they are not invariably a sign of illness and also occur in "normal" individuals. Evidence indicates that psychotic hallucinations lie on a continuum with normal experiences, and many more people experience hallucinations than meet criteria for clinical psychosis. In addition to a symptomatic continuum between normal individuals and patients with psychosis, there is evidence that hallucinatory experiences in nonclinical and clinical samples may share the same underlying etiologic influences, including sociodemographic risk factors and neurocognitive mechanisms. Predictors of patient status include beliefs about hallucinations, negative mood, and perceived lack of control.

---

### Occurrence and phenomenology of hallucinations in the general population: a large online survey [^114NQXqG]. Schizophrenia (2022). Medium credibility.

Fourthly, previous studies in the general population have demonstrated an association between the concurrent presence of hallucinations and delusions, a finding that we were able to replicate within our sample. This finding corresponds with neurobiological models of the interaction between hallucinations and delusions in psychosis. Altogether, our findings suggest that even when applying a very broad definition of hallucinations, they can be closely entwined with the presence of delusions in the general population.

Fifthly, in each sensory modality, we recognized subgroups of participants with more severe phenomenological presentations. From a clinical perspective, these subgroups are of specific interest, since they might be in need of care. Among these subgroups are individuals who experience distress or disfunctioning due to their hallucinations, those who experience hallucinations with a high frequency and/or a long duration, those who experience hallucinations with a negative content, those who have a tendency to comply to dangerous commands issued by their voices, those who report hallucinations associated with previous bothersome experiences, those who present with comorbid delusions, and those who report a lack of insight. For scientific purposes, these subgroups, as well as those experiencing highly specific hallucination types (e.g. musical hallucinations, auditory-verbal hallucinations, complex visual hallucinations, bereavement hallucinations, or hypnagogia,) can provide important anchor points for advancing our understanding of the mechanisms underlying hallucinations. Hallucinations are increasingly approached as a phenomenon that occurs across diagnoses, with heterogeneous origins (e.g. increased striatal dopamine, decreased cholinergic activity, social deafferentation, sensory deafferentation). Indeed, rather than one 'typical' phenomenological presentation of hallucinations per disorder, as depicted in Supplementary Table 2, increasing evidence on hallucination phenomenology shows both overlap between diagnostic groups, as well as within-group heterogeneity. Therefore, the chances of finding common underlying pathways of hallucinations are likely to increase by grouping people with phenomenologically homogeneous presentations (i.e. 'subtyping'), regardless of diagnosis, and studying and comparing biomarkers within and between these groups (i.e. 'deep phenotyping'). We, therefore, recommend to incorporate phenomenological measures in future hallucination research, preferably aided by extensive phenomenological subtyping.

---

### Tolcapone [^117NHdQa]. FDA (2020). Medium credibility.

Hallucinations/Psychotic-Like Behavior:

In clinical trials, hallucinations developed in approximately 5% of patients treated with placebo, compared to 8% and 10% of patients treated with 100 mg or 200 mg three times per day, respectively. Hallucinations led to drug discontinuation and premature withdrawal from clinical trials in 0.3% of patients treated with placebo, compared to 1.4% and 1.0% of patients treated with Tolcapone tablets 100 mg or 200 mg Tolcapone tablets three times per day, respectively. Hallucinations led to hospitalization in 0.0% of patients in the placebo group, compared to 1.7% and 0.0% of patients treated with 100 mg or 200 mg Tolcapone tablets three times per day, respectively.

In general, hallucinations present shortly after the initiation of therapy with tolcapone (typically within the first 2 weeks). Clinical trial data suggest that hallucinations associated with tolcapone use may be responsive to levodopa dose reduction. Patients whose hallucinations resolved had a mean levodopa dose reduction of 175 mg to 200 mg (20% to 25%) after the onset of the hallucinations. Hallucinations were commonly accompanied by confusion and to a lesser extent sleep disorder (insomnia) and excessive dreaming. The incidence of hallucination may be increased in elderly patients over 75 years treated with Tolcapone tablets (see Geriatric Use).

Postmarketing reports indicate that patients may experience new or worsening mental status and behavioral changes, which may be severe, including psychotic-like behavior during Tolcapone tablets treatment or after starting or increasing the dose of Tolcapone tablets. Other drugs prescribed to improve the symptoms of Parkinson's disease may have similar effects on thinking and behavior. This abnormal thinking and behavior may present with one or more symptoms, including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium.

Ordinarily, patients with a major psychotic disorder should not be treated with Tolcapone tablets because of the risk of exacerbating psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of Tolcapone tablets.

---

### The ASAM clinical practice guideline on alcohol withdrawal management [^113MvKKV]. Journal of Addiction Medicine (2020). High credibility.

Alcohol hallucinosis — clinical presentation and classification — is described as hallucinations that occur in the absence of other clinically prominent withdrawal signs and symptoms such as clear delirium, and hallucinosis consists of primarily auditory hallucinations but may include visual hallucinations and delusions. It is unclear if alcohol hallucinosis is part of alcohol withdrawal syndrome or a complication of chronic alcohol use unrelated to withdrawal, and alcohol hallucinosis is currently diagnosed as Alcohol-Induced Psychotic Disorder using the DSM-5.

---

### A review of multimodal hallucinations: categorization, assessment, theoretical perspectives, and clinical recommendations [^111NERuV]. Schizophrenia Bulletin (2021). Medium credibility.

Introduction

Various definitions have been advanced for "hallucinations", but there is general consensus that a hallucination can be defined as a sensory experience that resembles veridical perception without having a corresponding sensory stimulation from the external environment. Hallucinations can occur in all senses, including auditory, visual, olfactory, kinesthetic, and more. Hallucinatory experiences span nosological categoriesand are a clinical manifestation of many psychiatric disorders (schizophreniaand bipolar), neurodegenerative diseases (dementia with Lewy bodies [DLB]), and Parkinson's disease psychosis [PDP]), as well as sensory disorders like hearing impairment or eye disease.

Traditionally, hallucinations are often assumed to occur in one modality at a time (unimodal) and can be associated with different disorders — auditory hallucinations (AHs) in schizophreniaand visual hallucinations (VHs) in DLB. Where hallucinations do occur in different modalities, the predominant understanding is that they occur at different times (ie, they are not fused/simultaneous, like seeing and hearing a talking head; though see). Consequently, clinical assessments have had a focus on single modalities, thus biasing data collection toward unimodal hallucinations in potentially problematic ways. Nevertheless, growing recognition that hallucinations may occur in multiple modalities has shifted the attention to a systematic search for such multimodal phenomena.

Despite the lack of in-depth scrutiny in the field, accounts of hallucinations across all senses can be traced through time. Historical examples include medieval descriptions of spiritual voice hearing, such as those by Margery Kempe, who did not just hear the "voice of God" but also had visions and other sensory experiences. A recent case studyshows the experience of Mr T. A. a patient with schizophrenia who saw and heard humanoid creatures associated with a foul smell and who could go through his body, causing him unpleasant coenesthetic sensations (disorder of bodily perception). Such examples challenge the notion that unimodal hallucinations are the overwhelmingly prevalent clinical manifestations of psychiatric and organic disorders, and highlight the need for more accurate clinical assessment and management.

While hallucinations across multiple senses are starting to attract increasing research interest, several outstanding questions need to be addressed. This review, therefore, focuses on "multimodal hallucinations" (MMHs), ie, hallucinations that co-occur in different modalities, either in a simultaneous or in a sequential (serial) manner, with the overall objective of providing an overview of the field, highlight areas that require further scrutiny and identify issues of potential clinical importance.

---

### American psychiatric association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. second edition [^114Qd6qB]. The American Journal of Psychiatry (2007). Medium credibility.

APA practice guideline — psychosis and agitation in dementia: Psychosis and agitation occur commonly in patients with dementia and are important targets of psychiatric intervention. In DSM-IV-TR, Alzheimer's disease and other dementias with delusions and hallucinations and Alzheimer's disease with behavioral disturbances are classified separately, and provisional criteria for psychosis of Alzheimer's disease have been published; in clinical practice, however, these symptoms frequently co-occur.

---

### Occurrence and phenomenology of hallucinations in the general population: a large online survey [^1163gvt1]. Schizophrenia (2022). Medium credibility.

Lastly, in contemplation of maintaining the overall accessibility and non-clinical character of the study, it was not possible to incorporate clinical determinants (i.e. medical history, medication use) into this survey. Therefore, we were unable to assess the which extent our included sample overlaps with clinical populations, and in what context the reported hallucinations occurred.

Based on an online survey among over 10,000 participants, this is the first large study to provide an extensive amount of phenomenological information about hallucinations and other misperceptions in four sensory modalities in the general population. Notable findings included the high overlap of hallucinations between two or more sensory modalities, the content of TH, OH, and non-verbal AH, the stepwise increase in delusions in participants with more recent hallucinations, and, most importantly, the heterogeneous phenomenology with which hallucinations and other misperceptions presented, revealing a spectrum-like distribution of severity, and substantial numbers of participants with more severe presentations, such as those with distressing (10.5–16.8%) or debilitating hallucinations (12.7–17.3%). Our findings indicate that misperceptions are both common and phenomenologically diverse, and potentially distributed along a phenomenological continuum in the general population. Apart from the added value for destigmatization and psycho-educative objectives, our observations emphasize the importance of the phenomenological assessment of hallucinations, since they can provide important anchor points for clinical and scientific purposes.

---

### Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and adolescents [^117XYyW5]. Child and Adolescent Psychiatric Clinics of North America (2013). Low credibility.

Recognizing positive psychotic symptoms and their diagnostic context in youth is challenging. A large minority say they "hear things others do not hear", though they seldom present with complaints of hallucinations or delusions. Few have schizophrenia spectrum disorder, but many have other psychiatric disorders. Frequently, they have psychotic symptoms for an extended period before diagnosis. Clinicians should understand psychotic symptoms and their differential diagnoses. This article reviews the epidemiology, associated diagnoses, and prognosis of hallucinations and delusions in youth. Strategies for optimizing the clinical diagnostic interview, appropriate laboratory tests, indications for psychological testing, and rating scales are reviewed.

---

### The relationship between dissociation and symptoms of psychosis: a meta-analysis [^114hEcK2]. Schizophrenia Bulletin (2020). Medium credibility.

Evidence suggests that dissociation is associated with psychotic experiences, particularly hallucinations, but also other symptoms. However, until now, symptom-specific relationships with dissociation have not been comprehensively synthesized. This is the first prospectively registered (CRD42017058214) meta-analysis to quantify the magnitude of association between dissociative experiences and all symptoms of psychosis. MEDLINE, PsycINFO, PubMed, and Scopus databases were searched using exhaustive terms denoting dissociation and psychotic symptoms. We included both nonclinical (58 studies; 16 557 participants) and clinical (46 studies; 3879 patient participants) samples and evaluated study quality. Ninety-three eligible articles considering 20 436 participants were retained for analysis. There was a robust association between dissociation and clinical and nonclinical positive psychotic symptoms (r = .437; 95%CI: .386 -.486), with the observed effect larger in nonclinical studies. Symptom-specific associations were also evident across clinical and nonclinical studies, and included significant summary effects for hallucinations (r = .461; 95%CI: .386 -.531), delusions (r = .418; 95%CI: .370 -.464), paranoia (r = .447; 95%CI: .393 -.499), and disorganization (r = .346; 95%CI: .249 -.436). Associations with negative symptoms were small and, in some cases, not significant. Overall, these findings confirm that dissociative phenomena are not only robustly related to hallucinations but also to multiple positive symptoms, and less robustly related to negative symptoms. Our findings are consistent with proposals that suggest certain psychotic symptoms might be better conceptualized as dissociative in nature and support the development of interventions targeting dissociation in formulating and treating psychotic experiences.

---

### Culture and hallucinations: overview and future directions [^116ehwuq]. Schizophrenia Bulletin (2014). Low credibility.

It is only in the 20th century, as Leudar and Thomaspoint out, that hallucinations have been described as exclusively the sign of an illness. As a result, the term "hallucination" can carry stigma. Nonetheless, events that appear technically to be hallucinations and that conform to popular expectations of the presence of God are still often reported as religious events in popular Western media.

---

### Collaborative care in the identification and management of psychosis in adolescents and young adults [^117FWnvp]. Pediatrics (2021). High credibility.

Psychotic-like symptoms presenting in youth — prevalence and course — include auditory hallucinations with age-related reporting. In a pediatric mood and anxiety disorders clinic, approximately 10% of youth (n = 2031) had psychotic symptoms, and a median of 17% of 9- to 12-year-olds and a median of 7.5% of 13- to 18-year-olds report auditory hallucinations. Persistence of hallucinations into adolescence increases risk of developing psychosis five- to sixfold; in adolescents with hallucinations half reported no symptoms after 1 year, but a 2-year prospective cohort reported 51% persistence or worsening of psychotic symptoms after 2 years.

---

### Rasagiline mesylate (rasagiline) [^1167voYw]. FDA (2025). Medium credibility.

5.8 Hallucinations / Psychotic-Like Behavior

In the monotherapy study (Study 1), the incidence of hallucinations reported as an adverse event was 1.3% in patients treated with rasagiline 1 mg and 0.7% in patients treated with placebo. In Study 1, the incidence of hallucinations reported as an adverse reaction and leading to drug discontinuation and premature withdrawal was 1.3% in patients treated with rasagiline 1 mg and 0% in placebo-treated patients.

When studied as an adjunct therapy without levodopa (Study 2), hallucinations were reported as an adverse reaction in 1.2% of patients treated with 1 mg/day rasagiline and 1.8% of patients treated with placebo. Hallucinations led to drug discontinuation and premature withdrawal from the clinical trial in 0.6% of patients treated with rasagiline 1 mg/day and in none of the placebo-treated patients.

When studied as an adjunct to levodopa (Study 3), the incidence of hallucinations was approximately 5% in patients treated with rasagiline 0.5 mg/day, 4% in patients treated with rasagiline 1 mg/day, and 3% in patients treated with placebo. The incidence of hallucinations leading to drug discontinuation and premature withdrawal was about 1% in patients treated with 0.5 mg rasagiline and 1 mg rasagiline/day, and 0% in placebo-treated patients [see Adverse Reactions (6.1)].

---

### Hallucinations in children and adolescents [^1124gtAj]. Current Psychiatry Reports (2005). Low credibility.

Clinicians need to consider a wide range of differential diagnoses when children and adolescents present with hallucinations. This includes considering whether it is a developmentally normal phenomenon or if there is a psychiatric, medical, or neurologic diagnosis. Nonpsychotic children with hallucinations can be differentiated from psychotic children. Nonpsychotic children who are at risk (or prodromal) for future psychosis can be differentiated from nonprodromal healthier children. We examine the epidemiology, prognosis, and neurobiological research. Lastly, we discuss treatment approaches, including medication and cognitive behavioral therapy.

---

### Meta-analytic evidence for the plurality of mechanisms in transdiagnostic structural MRI studies of hallucination status [^1112gVDy]. EClinicalMedicine (2019). Medium credibility.

The multimodality of hallucinations is under-documented and under-researched, with < 2% of studies included in this review probing hallucinations beyond audition or vision. However, 30–50% of schizophrenia or PD patients report hallucinations in more than one modality,: olfactory hallucinations are present in 10–13.7%, and tactile sensations frequently co-occur with auditory hallucinations. Despite the dimensionality of hallucinations, many questionnaires and theoretical models target unimodal accounts. Non-clinical individuals who hallucinate or hear voices are receiving increasing interest in scientific research, yet only one study in this review assessed a structural correlate (cortical thickness) of hallucinations in this population. Similarly, no studies investigated brain structure or function of hallucinations in borderline personality disorder, in spite of a high point prevalence of 43%. Although hallucinations are recognized to occur across diagnostic boundaries, the current scope of transdiagnostic research on hallucinations remains narrow.

---

### Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations [^112J6ELo]. Journal of Alzheimer's Disease (2010). Low credibility.

Hallucinations in Alzheimer's disease (AD) may indicate greater cortical cholinergic deficits. Rivastigmine has shown larger treatment benefits versus placebo in dementia with Lewy bodies and Parkinson's disease dementia patients with hallucinations. In this retrospective, hypothesis-generating analysis, we investigated whether hallucinations in AD were associated with greater treatment benefits with rivastigmine. Data were pooled from two randomized, double-blind, 6-month, mild-to-moderate AD trials comparing rivastigmine with placebo. Co-primary efficacy parameters were the Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus). Efficacy data were analyzed for two sub-populations: those with and those without hallucinations at baseline. Of 927 patients, 194 (21%) reported hallucinations at baseline. Hallucinators tended to have greater decline on placebo on all outcome measures. On the ADAS-cog, mean rivastigmine - placebo differences of 3.7 points in hallucinators and 2.2 points in non-hallucinators were reported at 6 months (both p < 0.001). In hallucinators, a significant rivastigmine - placebo difference of -1.0 points (a beneficial effect) was seen on the CIBIC-plus at 6 months (p < 0.001). Non-hallucinators showed a smaller significant treatment difference of -0.3 points (p < 0.05). Interaction testing suggested that differences in treatment effects were significant between hallucinators and non-hallucinators. Hallucinations predicted greater treatment responses to oral rivastigmine.

---

### Understanding hallucinations in probable Alzheimer's disease: very low prevalence rates in a tertiary memory clinic [^111QASYe]. Alzheimer's & Dementia (2018). Low credibility.

Introduction

Averaging at 13.4%, current literature reports widely varying prevalence rates of hallucinations in patients with probable Alzheimer's disease (AD), and is still inconclusive on contributive factors to hallucinations in AD.

Methods

This study assessed prevalence, associated factors and clinical characteristics of hallucinations in 1227 patients with probable AD, derived from a tertiary memory clinic specialized in early diagnosis of dementia. Hallucinations were assessed with the Neuropsychiatric Inventory.

Results

Hallucination prevalence was very low, with only 4.5% (n = 55/1227) affected patients. Hallucinations were mostly visual (n = 40/55) or auditory (n = 12/55). Comorbid delusions were present in over one-third of cases (n = 23/55).

Hallucinations were associated with increased dementia severity, neuropsychiatric symptoms, and a lifetime history of hallucination-evoking disease (such as depression and sensory impairment), but not with age or gender.

Discussion

In the largest sample thus far, we report a low prevalence of hallucinations in probable AD patients, comparable to rates in non-demented elderly. Our results suggest that hallucinations are uncommon in early stage AD. Clinicians that encounter hallucinations in patients with early AD should be sensitive to hallucination-evoking comorbidity.

---

### Ropinirole hydrochloride [^113w98t4]. FDA (2025). Medium credibility.

5.4 Hallucinations/Psychotic-Like Behavior

In double-blind, placebo-controlled, early-therapy trials in patients with Parkinson's disease who were not treated with L-dopa, 5.2% (8 of 157) of patients treated with ropinirole tablets reported hallucinations, compared with 1.4% of patients on placebo (2 of 147). Among those patients receiving both ropinirole tablets and L-dopa in advanced Parkinson's disease trials, 10.1% (21 of 208) were reported to experience hallucinations, compared with 4.2% (5 of 120) of patients treated with placebo and L-dopa.

The incidence of hallucination was increased in elderly patients (i.e., older than 65 years) treated with extended-release ropinirole tablets [see Use in Specific Populations (8.5)].

Postmarketing reports indicate that patients with Parkinson's disease or RLS may experience new or worsening mental status and behavioral changes, which may be severe, including psychotic-like behavior during treatment with ropinirole tablets or after starting or increasing the dose of ropinirole tablets. Other drugs prescribed to improve the symptoms of Parkinson's disease or RLS can have similar effects on thinking and behavior. This abnormal thinking and behavior can consist of one or more of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, symptoms of mania (e.g., insomnia, psychomotor agitation), disorientation, aggressive behavior, agitation, and delirium.

Patients with a major psychotic disorder should ordinarily not be treated with ropinirole tablets because of the risk of exacerbating the psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of ropinirole tablets [see Drug Interactions (7.3)].

5.5 Dyskinesia

Ropinirole tablets may cause or exacerbate pre-existing dyskinesia in patients treated with L-dopa for Parkinson's disease. In double-blind, placebo-controlled trials in advanced Parkinson's disease, dyskinesia was much more common in patients treated with ropinirole tablets than in those treated with placebo. Among those patients receiving both ropinirole tablets and L-dopa in advanced Parkinson's disease trials, 34% were reported to experience dyskinesia, compared with 13% of patients treated with placebo [see Adverse Reactions (6.1)]. Decreasing the dose of dopaminergic medications may ameliorate this adverse reaction.

---

### Health supervision for children with 22q11.2 deletion syndrome: clinical report [^113icwM7]. Pediatrics (2025). High credibility.

Psychiatric screening in primary care — screen for psychosis symptoms at routine visits. "Screen for symptoms of hallucinations and delusions at all primary care visits". "Any report of hallucinations should be investigated".

---

### Hallucinations and the spectrum of psychosis in Parkinson's disease [^116a79qj]. Journal of the Neurological Sciences (2017). Low credibility.

Hallucinations and psychosis can be a part of Parkinson's disease and are considered to be a nonmotor symptom or a neuropsychiatric complication of the disease. Hallucinations of different modalities and delusions can occur beyond the common visual hallucinations. The various types of hallucinations and psychotic symptoms comprising the spectrum of Parkinson's disease psychosis is the subject of this review article.

---

### Paracingulate sulcus morphology and hallucinations in clinical and nonclinical groups [^114RqQ81]. Schizophrenia Bulletin (2019). Medium credibility.

Discussion

We used a previously validated visual classification technique and automated data-driven analysis to demonstrate that patients with schizophrenia who hallucinate exhibit reduced PCS length compared with both healthy controls and individuals who hallucinate in and have no clinical diagnosis. There was no difference between the hallucinating and nonhallucinating groups in terms of age, sex, handedness, years of education, and brain volume. Nonclinical individuals with hallucinations had longer PCS length in both hemispheres of the brain compared with patients with hallucinations, but showed no significant difference when compared with healthy control subjects. We verified these results using a data-driven gyrification analysis, finding differences in lGI in regions surrounding the PCS between patients with hallucinations and healthy controls, but not between nonclinical individuals with hallucinations and either healthy controls or patients with hallucinations. Together, these findings suggest that the association of shorter PCS length with hallucinations is specific to patients with a psychotic disorder.

These results are in line with previous findings that the reality monitoring impairments associated with hallucinations in schizophrenia may not extend to nonclinical individuals with hallucinations. The findings are thus consistent with the framework outlined in the Introduction section which proposes differences in the mechanisms underlying hallucinations in clinical and nonclinical groups (figure 2). This framework suggests that nonclinical hallucinations are predominantly associated with sensory hyperactivity, without the impairment in the reality monitoring process and morphological differences in paracingulate cortex associated with hallucinations in patients with schizophrenia.

Further evidence for the proposed framework comes from the failure to detect dopaminergic dysfunction in nonclinical individuals with hallucinations. Increased dopamine synthesis has been associated with the development of psychosis (eg, Howes et al,), and suggested to relate to psychotic experience through aberrant processing of salience. This failure to detect increased dopamine synthesis in nonclinical individuals with hallucinations suggests further differences at the neurobiological level which may be associated with the process of reality discrimination. This may in part explain the phenomenological differences in the experience of hallucinations in individuals with and without a clinical diagnosis.

---

### Distinguishing neuroimaging features in patients presenting with visual hallucinations [^113WJZ9f]. AJNR: American Journal of Neuroradiology (2016). Low credibility.

Visual hallucinations are relatively uncommon presentations in medical and psychiatric clinics, where they are generally regarded as a marker of possible underlying "organic" brain disease. Thus, patients with visual hallucinations are often referred for imaging of the brain. This article presents a pragmatic approach for the radiologist reviewing such imaging. Because conditions that can present with visual hallucinations are legion, a familiarity with the features of the hallucinations themselves, which can serve as clues to the underlying cause, can be helpful in interpreting such cases. We consider the nature of visual hallucinations and the mechanisms underlying their formation. We then provide a framework to guide the search for their cause, first in terms of focal lesions along the visual pathway and then global conditions affecting > 1 region.

---

### Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology [^115EcQ5r]. Neurology (2001). Medium credibility.

Dementia with Lewy bodies (DLB) — clinically defined by dementia with gait/balance disorder, prominent hallucinations and delusions, sensitivity to traditional antipsychotics, and fluctuating alertness, diagnostic reliability and accuracy are limited: Two Class II studies found interrater reliability "to be relatively low", one Class I study found sensitivity low but specificity high against neuropathology, and Five Class III studies also showed low sensitivities with higher specificities for Consortium for DLB criteria. In a prospective registry with neuropathologically confirmed cases, hallucinations, depression, delusions, and delusional misidentification were "significantly higher in patients with DLB than AD", although "all of these features occurred in patients with AD" as well.

---

### Clinical reasoning: a 48-year-old woman with 6 months of vivid visual hallucinations [^115K7FQZ]. Neurology (2022). Medium credibility.

Visual hallucinations are frequently encountered in clinical practice. It is critical for neurologists, particularly those in training, to develop a systematic approach for evaluating patients presenting with such unique and often perplexing symptoms. In this study, we present the case of a 48-year-old woman who developed vivid visual hallucinations after receiving nivolumab for melanoma. We discuss the broad differential diagnosis for visual hallucinations and how history and examination can guide one's evaluation.

---

### Hallucinations in older adults: a practical review [^116sAA1e]. Schizophrenia Bulletin (2020). Medium credibility.

Purpose of Treatment

For some disorders, such as intoxication, psychotic depression, and schizophrenia, hallucinations may respond well to treatment of the underlying disorder. However, in other disorders, such as dementia, vision or hearing loss, or Parkinson's disease, this is not the case. In such instances, additional treatment aimed specifically at hallucinations may be indicated. For the treatment of hallucinations, the most important question is what the aim of treatment should be. There are a number of answers frequently given to this question:

I want to understand why I experience these hallucinations.
I want to be competent to handle these hallucinations.
I want to get rid of these hallucinations.

For Purpose 1: Psychoeducation.

If the response to this question is in line with answer 1, then psychoeducation is the treatment of choice. In one or more sessions, the patient and his/her loved one can be provided with information about how perception is accomplished in the brain, how this process can go awry, and which factors can precipitate hallucinations. A good start for psychoeducation is to ask the patient what he/she already knows and which explanation he/she currently uses for this experience. From there, unhelpful explanations can be corrected and new knowledge can be added to improve disease insight.

---

### Hallucinations and disturbed behaviour in the critically ill: incidence, patient characteristics, associations, trajectory, and outcomes [^114tyNRP]. Critical Care (2025). Medium credibility.

Trajectory

Hallucinations were most common on the day after ICU admission with the majority occurring within the first three days (Fig. 1). The alluvial plot shown in Fig. 2 describes the trajectory of all patients who developed at least one episode of hallucinations ICU. It shows that approximately one third of patients with hallucinations on day one continued to experience hallucinations on day two and that approximately two thirds of such patients achieved resolution by day five. On the other hand, approximately one of every six patients who were free of hallucinations on day one or day two went on to develop hallucinations on the following day, with a similar rate of resolution over time.

Fig. 1
Cumulative incidence plot of hallucination. Cumulative incidence plot of the first episode of hallucination considering ICU mortality and discharged alive as competing events

Fig. 2
Trajectory of hallucination during the first 5 days. Alluvial plot demonstrating the trajectory of hallucinations in patients who experience them in ICU. Blue are patients without hallucination on day 0 and red are patients with hallucination on day 0

---

### Understanding hallucinations in probable Alzheimer's disease: very low prevalence rates in a tertiary memory clinic [^113UDjqx]. Alzheimer's & Dementia (2018). Low credibility.

Indeed, we observed significant associations between the presence of hallucinations and both decreased MMSE scores and an increased CDR. Hallucination prevalence rates increased with intensifying categories of dementia severity, with percentages up to 10% in the group with MMSE scores of 10 or less. These observations correspond with previous studies suggesting the uncommonness of hallucinations in early stage AD, and an increase in cumulative hallucination prevalence with disease progression. The mean age of our sample was younger than that of other cohorts, but, in our sample, hallucinating and nonhallucinating subjects' age did not differ significantly.

Thirty-eight percent of hallucinating subjects reported a lifetime history of hallucination-evoking diagnoses; significantly higher than the nonhallucinating control group (25%). A similar trend was observed with regard to the use of hallucination-inducing medication. Also, hallucinating subjects had a significantly elevated NPI score regardless of the hallucination score, indicating an increased overall presence and severity of neuropsychiatric symptoms. These observations imply that the presence of hallucinations in our sample does not necessarily have to be attributed to a diagnosis of AD alone but may also be evoked by other diagnoses or medication use. This implication stresses the importance of proper hallucination assessment in patients with AD. Clinicians who encounter hallucinations in patients with AD should consider the broad diagnostic spectrum in which hallucinations occur, such as dementia with Lewy bodies, delirium, psychotic or affective disorders, and sensory impairment, so that treatment options can be properly adjusted. As such, we recommend clinicians who encounter hallucinations in early stage AD patients to actively approach them within the context of medication use and current and prior disease.

---

### Clinical practice guideline: allergic rhinitis [^1144AWcp]. Otolaryngology — Head and Neck Surgery (2015). Medium credibility.

Guideline purpose and scope — this guideline provides "evidence-based recommendations for clinicians managing patients with tinnitus", targeting "any clinician, including nonphysicians", and limits the target patient population to "adults (18 years and older) with primary tinnitus that is persistent and bothersome". Patients with identifiable causes of hearing loss such as Ménière's disease, sudden SNHL, otosclerosis, and VS are discussed, but "patients with these identifiable and other causative diagnoses of secondary tinnitus are excluded from this guideline", and "the guideline also excludes patients with pulsatile tinnitus, or tinnitus related to complex auditory hallucinations or hallucinations related to psychosis or epilepsy". "Clinicians should decide whether to apply these recommendations to patients with these conditions on an individualized basis".

---

### Collaborative care in the identification and management of psychosis in adolescents and young adults [^116EVXQ7]. Pediatrics (2021). High credibility.

Appendix 2 — questions for assessing psychotic-like experiences in adolescents provide example phrasing to explore hallucinations, paranoia, thought insertion, special messages, and symptom context, and include reality-testing prompts to gauge insight and alternative explanations.

---

### American psychiatric association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. second edition [^116AhpfN]. The American Journal of Psychiatry (2007). Medium credibility.

Neuropsychiatric assessment in dementia — prevalence, monitoring, and target symptoms: Ninety percent of patients with dementia develop a neuropsychiatric or behavioral symptom during the course of the disease, so it is important for the psychiatrist to periodically assess for noncognitive psychiatric symptoms and for progression of cognitive decline, with regular monitoring to detect new symptoms and adapt treatment. In Alzheimer's disease, depression is reported more commonly early in the illness, whereas delusions and hallucinations are more common in the middle and later stages, and it is particularly important to look for the emergence of such symptoms after a medication dose has been lowered or discontinued. Ongoing assessment should address depression, suicidal ideation or behavior, hallucinations, delusions, agitation, aggressive behavior, disinhibition, sexually inappropriate behavior, anxiety, apathy, and disturbances of appetite and sleep; cognitive symptoms that almost always require assessment include impairments in memory, executive function, language, judgment, and spatial abilities, and it is often helpful to track cognitive status with a structured mental status examination while watching for practice effects if the same instrument is used repeatedly.

---

### Occurrence and phenomenology of hallucinations in the general population: a large online survey [^115ce8Pk]. Schizophrenia (2022). Medium credibility.

Although epidemiological studies report that hallucinations occur in 6–15% of the general population, little is known about their phenomenology. To overcome this paucity, this study investigates the phenomenological characteristics of hallucinations in the general population, by using a nationally promoted online survey to assess hallucination phenomenology in four sensory modalities, through a self-report version of the Questionnaire for Psychotic Experiences (QPE), in 10,448 participants (aged 14–88 years). The phenomenology of hallucinations was assessed if hallucinations reportedly occurred in the past month. In the past month, auditory hallucinations were reported most frequently (29.5%), followed by visual (21.5%), tactile (19.9%), and olfactory hallucinations (17.3%); hallucinations in two or more modalities were reported by 47.6%. Substantial numbers of participants rated their hallucinations as severe, due to negative content (16.0–31.6%), previous bothersome experiences (14.8–20.2%), ensuing distress (10.5–16.8%), and/or ensuing disfunctioning (12.7–17.3%). Decreased insight was found in 10.2–11.4%. Hypnagogia was reported by 9.0–10.6%, and bereavement hallucinations by 2.8%. Despite a low prevalence of delusions (7.0%), these phenomena were significantly associated with recent hallucinations, observed in up to 13.4% of the participants with hallucinations during the past week (p < 0.001). Our results indicate a wide variety of the phenomenology of hallucinations in the general population and support the existence of a phenomenological continuum.

---

### American psychiatric association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. second edition [^115faHJa]. The American Journal of Psychiatry (2007). Medium credibility.

APA practice guideline — Dementia with Lewy bodies and Parkinson's disease dementia are defined by whether Parkinson's disease precedes cognitive impairment by more than 1 year (Parkinson's disease dementia) or whether cognitive impairment is the dominant symptom (dementia with Lewy bodies), and whether these entities are one condition or distinct ones remains unresolved. Parkinson's disease is a slowly progressive neurological condition characterized by tremor, rigidity, bradykinesia, and postural instability with onset typically in middle to late life. In one large longitudinal study, dementia developed in nearly 80% of patients followed for 8 years. The dementia associated with Parkinson's disease has an insidious onset and slow progression with cognitive and motor slowing, executive dysfunction, and impairments in memory retrieval and flexibility; Parkinson's disease is important to psychiatrists because of the high prevalence of associated depression and the frequent occurrence of psychotic symptoms such as visual hallucinations during pharmacological treatment of the primary motor deficit.

---

### Diagnosis of delirium: a practical approach [^114nV3Fy]. Practical Neurology (2023). Medium credibility.

Delirium is an acute disorder of fluctuating attention and awareness with cardinal features that allow it to be positively distinguished from other causes of an acute confusional state. These features include fluctuations, prominent inattentiveness with other cognitive deficits, a change in awareness and visual hallucinations. We describe a framework for diagnosing delirium, noting the need to consider certain caveats and differential diagnoses. Delirium is a clinical diagnosis where a thorough history and clinical examination are much more helpful diagnostically than any single test or combination of tests.

---

### The ASAM clinical practice guideline on alcohol withdrawal management [^115KAKnm]. Journal of Addiction Medicine (2020). High credibility.

Alcohol-induced psychotic disorder — recommendations and pharmacotherapy signals: Recommendation VI.22 states, "If available and applicable, existing institutional/hospital-associated delirium protocols can be used for supportive care of patients with an alcohol-induced psychotic disorder", Recommendation VI.23 states, "The treatment of alcohol-induced psychotic disorder may require consultation with a psychiatrist", and Recommendation VI.24 states, "The treatment of alcohol-induced psychotic disorder may require addition of antipsychotics". Symptoms of alcohol-induced psychosis consist of auditory hallucinations and possibly visual hallucinations and delusions, there is no established pharmacotherapy, but a randomized controlled trial of 50 patients showed diazepam to be effective at reducing hallucinations compared to placebo, and the Guideline Committee rated diazepam as an appropriate medication for the treatment of alcohol-induced psychosis while also concluding that it may be necessary to treat these patients with an additional antipsychotic medications to alleviate the symptoms. Patients experiencing alcohol-induced psychosis are at risk of developing acute delirium while in the inpatient setting and appropriate hospital-associated delirium protocols should be implemented, if available, to reduce the risk of delirium and associated health outcomes.

---

### The ASAM clinical practice guideline on alcohol withdrawal management [^114enreg]. Journal of Addiction Medicine (2020). High credibility.

Alcohol withdrawal special terms defines key concepts used in the guideline. Alcohol hallucinosis/alcohol-induced psychosis is described as a form of alcohol withdrawal that is distinct from delirium and other clinically prominent withdrawal syndromes and symptoms, characterized primarily by auditory hallucinations, paranoid symptoms and fear, with hallucinations that are generally third person and often derogatory and that may include secondary delusions or perseveration; it is unclear whether alcohol hallucinosis is part of alcohol withdrawal or a complication of chronic alcohol use unrelated to withdrawal, and currently it is diagnosed as alcohol-induced psychotic disorder in the Diagnostic and Statistical Manual 5 (DSM-5). Ambulatory withdrawal management is defined as withdrawal management that occurs in outpatient settings, including primary care and intensive outpatient/day hospital settings, with level of clinical expertise and frequency of monitoring varying widely within ambulatory withdrawal management settings. The terms delirium and seizure in this document refer to alcohol withdrawal-related seizure or alcohol withdrawal delirium, and alcohol withdrawal delirium has replaced the formerly used "delirium tremens". The document also describes dosing regimens used in alcohol withdrawal management and focuses on regimen types, including symptom-triggered dosing, which is described as an approach whereby patients are monitored through the use of a structured assessment scale.

---

### Multi-model assurance analysis showing large language models are highly vulnerable to adversarial hallucination attacks during clinical decision support [^112ACmFH]. Communications Medicine (2025). Medium credibility.

Results

Hallucination rates overall and model specific

The overall hallucination rate in all models under the default prompt was 65.9%, while the mitigating prompt reduced the rate to 44.2%. Under temperature 0, the overall hallucination rate was 66.5%. These rates represent averages across both long and short cases.

Without mitigation, hallucination rates were 64.1% for long cases versus 67.6% in short ones. With the mitigation prompt, rates dropped to 43.1% and 45.3% for long and short cases, respectively. With temperature set to zero, long cases had a hallucination rate of 64.7% and short cases 68.4% (Fig. 3).

Fig. 3
Hallucination rates by condition.

Overall hallucination rates by condition and case format (N = 5400).

Across all models, only 1.2% (65/5400) of outputs that were classified as non-hallucinations under the base prompt were re-classified as hallucinations when the mitigating prompt was applied.

Under default configuration settings, Distilled-DeepSeek had the highest hallucination rates (80.0% in long cases and 82.7% in short cases), while GPT4o had the lowest (53.3% for long cases and 50.0% for short cases) (Fig. 4). The other models ranged between 58.7% and 82.0% across case formats.

Fig. 4
Hallucination rates by model.

Spider diagram of hallucination rates by model and prompt type.

With the mitigation prompt, GPT4o reduced hallucinations to 20.7% for long cases and 24.7% for short cases. With temperature set to zero, hallucination rates remained similar to those observed under default settings (Table S1). Figure 5 presents some specific examples of cases in which the models did and did not hallucinate.

Fig. 5
Real examples of hallucinations.

Specific examples for cases of hallucinations (above) and non-hallucinations (below).

---

### American psychiatric association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. second edition [^114pie9L]. The American Journal of Psychiatry (2007). Medium credibility.

Dementia — associated neuropsychiatric and behavioral features include apathy, avolition, and withdrawal; depressed mood (with or without neurovegetative changes) with sleep disturbances and anxiety independent of depression; and suicidal behavior in mildly impaired individuals with insight into deficits. Patients may manifest "catastrophic reactions" to minor stressors, develop delusions (spousal infidelity, persecution, theft; misidentifications; and impostor delusions), and have hallucinations across sensory modalities, with visual hallucinations most common; some exhibit evening agitation or other behavioral disturbances referred to as "sundowning".

---

### Hallucinations as a risk marker for suicidal behaviour in individuals with a history of sexual assault: a general population study with instant replication [^113gVojx]. Psychological Medicine (2023). Medium credibility.

Main analyses

In both the 2007 and 2014 datasets, individuals with a history of sexual assault who also reported hallucinations were at increased odds of suicide attempt compared to individuals with a history of sexual assault but who did not report hallucinations (See Table 1). There was a significant interaction between sexual assault and hallucinations, such that hallucinations indexed risk for suicide attempt in excess of that explained by sexual assault [p < 0.001 in both the 2007 and 2014 dataset]. Whereas, in the 2007 study, 14% of individuals with a history of sexual assault who did not report hallucinations had one or more suicide attempt, 33% of individuals with a history of sexual assault who reported hallucinations had one or more suicide attempt. In the 2014 study, 19% of individuals with a history of sexual assault who did not report hallucinations had one or more suicide attempt compared to 52% of individuals with a history of sexual assault who reported hallucinations.

Table 1.
Relationship between hallucinations and suicide attempt in individuals with a history of sexual assault

Table 2 shows the prevalence of suicidal ideation and suicide attempts across four groups in the 2007 dataset: (1) individuals with neither a history of sexual assault nor hallucinations (reference group), (2) individuals without a history of sexual assault but who did report past-year hallucinations, (3) individuals with a history of sexual assault but who did not report past-year hallucinations, and (4) individuals with a history of sexual assault and who also reported hallucinations.

Table 2.
Suicidal ideation and attempt stratified by sexual assault history and hallucinations, 2007

Table 3 shows the prevalence of suicidal ideation and suicide attempts across four groups in the 2014 dataset: (1) individuals with neither a history of sexual assault nor hallucinations (reference group), (2) individuals without a history of sexual assault but who did report past-year hallucinations, (3) individuals with a history of sexual assault but who did not report past-year hallucinations, and (4) individuals with a history of sexual assault and who also reported hallucinations.

---

### Differences in regional cerebral blood flow during musical and verbal hallucinations [^1165uMEG]. Psychiatry Research (2002). Low credibility.

A 51-year-old male patient suffered from both musical and verbal hallucinations with insight. We performed three single photon emission computed tomographic scans with the patient in different conditions: baseline without hallucinations, musical hallucinations, and verbal hallucinations. Clearly, different patterns of regional cerebral blood flow (rCBF) were observed during musical and verbal hallucinations. The findings suggest that musical and verbal hallucinations are associated with different patterns of rCBF, possibly reflecting the different causes of the two types of hallucinations.

---

### Towards an integrative account of potential mechanisms mediating the path from sleep dysfunction to hallucinations [^114VxbtH]. Schizophrenia Bulletin (2025). Medium credibility.

Introduction

"[After a bad night of sleep the voices] would be a lot louder, and I would hear them more "

(Voice-hearer "V13",)

Over the past decade, manipulation studies have provided sound support for the causal role of sleep disruption in the occurrence of hallucinatory experiences. Disrupting sleep in healthy volunteers induces sub-clinical increases in hallucinatory experiences. Conversely, treating sleep disruption in students with insomnia lessens hallucinatory experiences, with over a third of the reduction in hallucinations attributable to improvements in insomnia. Further support for the causal argument comes from the temporality of effects: sleep disruption typically precedes, and is predictive of, a first episode of psychosis. While the relationship between insomnia and hallucinatory experiences is bidirectional, longitudinal evidence shows that the strongest path is from insomnia to later hallucinatory experiences. The current review seeks to take the causal argument further by identifying potential mediating mechanisms that might account for the path from sleep dysfunction to hallucinations.

We use a levels-of-explanations approach to identify potential causal pathways between sleep dysfunction and hallucinations from a phenomenological, psychological, neuronal, and neurophysiological perspective. This results in a candidate set of potential causal mechanisms, which in some cases may act across domains to explain the path from sleep dysfunction to hallucinations. Rather than definitively answering the question of why sleep dysfunction leads to hallucinations, the current study is meant as a hypothesis-generating account, guiding future research in advancing our understanding. "Sleep dysfunction" serves as an umbrella term covering the breadth of deviations from healthy sleep (eg, sleep deprivation/restriction, nightmares, and clinical insomnia). The most common sleep disorders, experienced by around half of people with psychosis, are insomnia and problematic nightmares. The majority of existing mechanistic research has focused on insomnia and sleep loss specifically; hence, this is the key focus of the review. The review sought to answer the following 5 research questions.

How do people with lived-experience of hallucinations describe the path from sleep dysfunction to hallucinations?
Which psychological factors mediate the association between sleep dysfunction and hallucinations?
How does neuronal connectivity affected by sleep make the brain more susceptible to hallucinations?
How do neurophysiological changes resulting from sleep dysfunction increase the risk of experiencing hallucinations?
Are there common pathways that hold across the four levels of explanation?

---

### Childhood visual hallucinations: a case report of idiopathic occipital epilepsy [^114qaqdm]. Journal of the American Academy of Child and Adolescent Psychiatry (2018). Low credibility.

Although various types of hallucinations are reported at high rates during childhood, the research focusing on visual hallucinations is relatively scarce. 1 Visual hallucinations have often been linked to biological causes and have been considered uncommon in psychiatric samples. However, recent studies suggest that almost 30% of visual hallucinations occur in the context of psychosis. 1 The risk of psychopathology is often a cause of concern when children report visual hallucinations, especially when associated with poor functioning. A detailed history must be taken to determine whether reported hallucinations are a phenomenon of typical development (for example, imaginary friends, or hypnopompic or hypnogogic hallucinations), a symptom of trauma or anxiety, or have another etiology. In the presence of confirmed distressing complex hallucinations, clinicians should clarify whether they are neurological in origin or are a symptom of an established psychiatric disorder.

---

### The ASAM clinical practice guideline on alcohol withdrawal management [^115Weo6n]. Journal of Addiction Medicine (2020). High credibility.

Alcohol-induced psychotic disorder — supportive care and treatments: if available and applicable, existing institutional/hospital-associated delirium protocols can be used for supportive care of patients with an alcohol-induced psychotic disorder. The treatment of alcohol-induced psychotic disorder may require consultation with a psychiatrist and may require addition of antipsychotics, and for patients experiencing hallucinations, diazepam may be considered a treatment option.

---

### The management of major depressive disorder: synopsis of the 2022 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline [^1139SwUx]. Annals of Internal Medicine (2022). High credibility.

Appendix K — MDD severity variants and psychotic features are described: individuals demonstrating more severe or atypical presentations, including marked physical slowness or marked agitation and somatic symptoms, are often referred to as melancholic depressions or depression with melancholia. People with severe depressive episodes may also develop psychotic symptoms (hallucinations and/or delusions), most commonly thematically consistent with negative, self-blaming cognitions and low mood, while others may develop psychotic symptoms unrelated to mood; in the latter case, the mood-incongruent psychotic symptoms prove difficult to distinguish from those that occur in other psychoses such as schizophrenia.

---

### Paracingulate sulcus morphology and hallucinations in clinical and nonclinical groups [^115Rz7P1]. Schizophrenia Bulletin (2019). Medium credibility.

The model can also accommodate the phenomenological differences often reported in the experience of clinical and nonclinical hallucinations. It is suggested that nonclinical hallucinations are unlikely to occur without hyper-activation of sensory cortices, which culminates in content which is unusually intense or vivid in nature. While a similar process is implicated for clinical hallucinations, this factor may be less significant, given the additional impact of impaired reality discrimination processes. Such an view can account for the lower frequency and duration of nonclinical, compared with clinical, hallucinations, as the experience of a nonclinical hallucination might depend on the sensory information surpassing, and being maintained at a level in excess of a hallucination threshold. Furthermore, nonclinical hallucinations are associated with a greater level of control than clinical hallucinations, which might be understandable in terms of the relative ability to down-regulate sensory activity, rather than to enhance the impaired reality discrimination process intrinsic to clinical hallucinations. It is not, however, suggested that the model can account for the entirety of the experiential differences in hallucinations between the groups; for example, it cannot explain the enhanced level of negative content that may be associated with clinical hallucinations.

Looking more broadly at the proposed model, there is also strong evidence supporting a role for ACC in the generation of hallucinations. Hunter et al'sdemonstration of spontaneous activity in speech-sensitive auditory cortex in healthy individuals also found this to be associated with activity within the ACC. Dorsal ACC/paracingulate activity has also been related to the monitoring and generation of internal and external speech in healthy individuals and in patients with schizophrenia. ACC activity during hallucinations has been reported in some, but not all state studies of hallucinations (eg, Diederen et al), in the generation of conditioned hallucinations in healthy individuals, and in self-induced hallucinations in hypnosis-prone individuals. Furthermore, a recent study into the processing of ambiguous speech in individuals with nonclinical hallucinations found that voice-hearers recognized the presence of speech in degraded sine-wave speech before control subjects, with the intelligibility response related to activity in both dorsal ACC and superior frontal gyrus. This suggests a role for ACC in the enhanced tendency of hallucination-prone individuals to extract meaningful linguistic content from ambiguous information.

---

### The relationship between delusions and hallucinations [^114DU437]. Current Psychiatry Reports (2006). Low credibility.

The origins of delusional beliefs have been a question of great interest for centuries. For many years, the widely held view was that there was a fundamental defect in reasoning in the patient that gave rise to the false belief. Much effort was directed at establishing the kind of defect and the circumstances that triggered it. The search for the basic reasoning defect has met with limited success, mainly because the flaws found in the reasoning of deluded persons are also found with substantial frequency in the general population. The co-occurrence of hallucinations and delusions is consistent with findings that repeated anomalous experiences of various kinds are followed by the development of delusions. In this case, it would be reasonable to regard the hallucinations as exercising a causative role in the development of delusions.

---

### Psychotic symptoms in Parkinson's disease. from description to etiology [^115BWnZM]. Journal of Neurology (2005). Low credibility.

Psychotic symptoms are common in Parkinson's disease (PD) and occur in at least 20% of medication-treated patients. Benign visual hallucinations usually appear earlier, while malignant hallucinations, confusional states, delusions, paranoid beliefs, agitation, and delirium become more frequent with disease progression. Virtually all antiparkinsonian drugs may produce psychotic symptoms. Cognitive impairment, increased age, disease duration and severity, depression, and sleep disorders have been consistently identified as independent risk factors for their development. Although the precise pathoetiologic mechanisms remain unknown, we review evidence that links ventral dopaminergic pathway dysfunction (overactivity) together with the involvement of other neurotransmitter system imbalances as likely contributors. The clinical importance of the proposed mechanism is that successful management of psychotic symptoms in PD may rely on a multitarget approach to restore neurotransmitter imbalances rather than focusing exclusively on the dopaminergic dysfunction.

---

### Collaborative care in the identification and management of psychosis in adolescents and young adults [^111cDWw2]. Pediatrics (2021). High credibility.

ASD — an adolescent case illustrates that a 14-year-old with auditory hallucinations of multiple fantasy characters had poor peer relationships and prior antipsychotic trials without efficacy; after evaluation he received an ASD diagnosis with negative genetic testing, was advised slow discontinuation of antipsychotic medication, and engaged in psychotherapy and a social skills group with improved social interactions.

---

### Disrupting sleep: the effects of sleep loss on psychotic experiences tested in an experimental study with mediation analysis [^1121hqST]. Schizophrenia Bulletin (2018). Low credibility.

Background

Insomnia co-occurs with and predicts psychotic experiences, especially paranoia and hallucinations. In a recent survey of 267692 individuals from 56 countries, sleep problems were associated with a 2-fold increased likelihood of endorsing that there was a plot to harm them (paranoia) or an experience of seeing visions or hearing voices (hallucinations). Insomnia also predicts an increased likelihood of reporting paranoia or hallucinations at a later time. These associations remained significant even after controlling for depression and anxiety. In clinical settings sleep difficulties co-occur with more severe psychotic symptoms in patients with schizophrenia spectrum disorders, are predictive of relapse of psychotic symptoms, and for transition from at risk mental state to first-episode psychosis.

Clearly, there is an association between insomnia and psychotic experiences. Yet, as identified by a recent systematic review of 66 studies, there is a need to directly test the causal role of insomnia, and to understand the mechanisms linking it with psychotic experiences. Such findings would inform the understanding of the etiology of psychotic experiences, and would also contribute to developing sleep interventions for patients with non-affective psychosis. To establish causation, studies are needed which manipulate the proposed causal variable (insomnia) to test the effect (on psychotic experiences). One approach is to improve insomnia while measuring psychotic experiences among individuals with existing sleep problems (with or without a psychotic disorder diagnosis). An improvement in sleep should lead to a lessening in psychotic experiences. A second approach is to disrupt sleep, with the prediction that psychotic experiences should worsen. In effect, with nonclinical individuals, this would temporarily simulate the development of psychotic experiences.

---

### From tones in tinnitus to sensed social interaction in schizophrenia: how understanding cortical organization can inform the study of hallucinations and psychosis [^11748cui]. Schizophrenia Bulletin (2014). Low credibility.

Hallucinations and the Sensory Hierarchy

How does activity captured during hallucinations relate to the hierarchical network described above? If spontaneous activation of a given cortical representation gives rise to a hallucination of that representation, one might make a number of predictions. The first is that simple hallucinations in a given modality involve cortical regions at a lower level of the sensory hierarchy than complex hallucinations, and, conversely, complex hallucinations involve cortical regions at a higher level of the hierarchy. Second, hallucinations involving a single modality (referred to clinically as isolated hallucinations) should relate to unimodal cortex, while hallucinations combining modalities (referred to clinically as multimodal hallucinations) should relate to heteromodal cortex or combinations of heteromodal and unimodal cortical activity. Third, even if arising de novo in a region, activity underlying a hallucination takes place within the context of a network and thus may propagate to other regions. Finally, in addition to sensory experience, conceptual psychological aspects of function implicit in heteromodal representation (eg, social interaction) might be incorporated into the overall phenomenology of the experience. Below, we examine the evidence supporting these predictions and their wider implications for hallucinations in schizophrenia.

---

### Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial [^112EY8HH]. The Lancet: Psychiatry (2015). Medium credibility.

The key efficacy question addressed in the design of the present study was whether CBT can improve sleep in patients with current psychotic experiences and insomnia. We assessed this question in the context of our translational research that aims to improve treatments for people with psychosis. The causal framework that we use leads to the initial aim of showing change in the targeted mechanism (eg, sleep disruption), hence the comparison of a sleep treatment (whereby the expectation is that sleep will improve) with continued standard care (whereby sleep patterns are likely to remain stable). The chosen design also addresses the important clinical question of the potential overall benefit provided when the intervention is added to standard care. From some perspectives, this question is key: "The primary question facing clinicians and policy makers is whether adding a particular form of treatment will significantly improve symptoms or functioning compared to the often-constrained services as usual". However, this question would only establish whether the extra treatment has benefits, not which elements of the package are actually necessary or whether there are better forms of treatment. These latter questions require different choices of control group in order to answer them. Nonetheless, our clinical impression is that, for example, the extra contact time alone provided by the CBT is an insufficient explanation for such large improvements in sleep in a patient group that typically has long-standing and complex problems. Indeed, CBT has already been shown to have benefit compared with attention-control conditions in the treatment of primary insomnia.

Sleep difficulties are a problem that patients with psychosis find distressing and very much wish to receive effective treatment for from mental health services. A large, multicentre trial is now needed that can establish the effects of CBT for insomnia, delivered by front-line mental health staff, both on sleep and psychotic experiences.

---

### Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial [^115436fe]. The Lancet: Psychiatry (2015). Medium credibility.

Results

The figure shows the trial profile. Between Dec 14, 2012, and May 22, 2013, and Nov 7, 2013, and Aug 26, 2014, we randomly assigned 50 patients to receive CBT plus standard care (n = 24) or standard care alone (n = 26), with the break in enrolment due to employment of a new trial therapist. 47 (94%) patients were from Oxford Health and three (6%) were from Northamptonshire Healthcare. The last assessments were completed on Feb 10, 2015. All 50 patients completed the baseline assessment. 48 (96%) patients provided follow-up data for the primary efficacy measures (figure). In the CBT group, the mean number of sessions received was 7.3 (SD 1.9). On the basis of at least four CBT sessions constituting a minimum therapeutic dose, 23 (96%) of 24 patients had a dose of the intervention. The actual number of treatment sessions attended in the 12 week period was three (n = 1), four (n = 1), five (n = 1), six (n = 4), seven (n = 5), eight (n = 7), nine (n = 2), ten (n = 2), or 11 (n = 1) sessions. The appendix shows descriptive comments about the intervention received from five of the first seven patients who had CBT.

Baseline and demographic characteristics were similar between groups (table 1). In line with other studies of persistent psychotic experiences, both groups included slightly more men, the average age was about 40 years, most participants were unemployed, and the main diagnosis was schizophrenia (table 1). There were high levels of depression in both groups (table 1), although BDI scores were not significantly correlated with level of insomnia at baseline (r = 0.07, p = 0.623). All but one patient (in the standard care alone group) met the Duke Structured Interview Schedule for Sleep Disorder Diagnoses criteria for insomnia disorder. Provision of standard care was similar between groups and was fairly stable during the trial (table 2). All but four participants (n = 3 given CBT, n = 1 given standard care alone) were taking antipsychotic medication (table 2). Most participants were also prescribed a hypnotic, anxiolytic, or antidepressant medication (19 [79%] in the CBT group, 21 [81%] in the standard care alone group; appendix). All participants were outpatients.

---

### Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia [^111PxcBW]. Bipolar Disorders (2005). Low credibility.

Objective

As there is very little research on the topic, we compared the frequency and the type hallucinations among hospitalized patients diagnosed with bipolar disorder (BPD) versus other major psychiatric illnesses.

Methods

At admission, all patients hospitalized at the Department of Psychiatry at the Freie Universität Berlin (1981–2001) underwent comprehensive assessments using the standardized Association for Methodology and Documentation in Psychiatry (AMDP) system. We used these data to compare risks and types of hallucinations and associated factors by bivariate and multivariate testing in patients diagnosed with BPD, major depression, or schizophrenia.

Results

At admission, the cross-sectional prevalence of current hallucinations among 4972 hospitalized subjects ranked: schizophrenia (61.1%), bipolar mixed (22.9%), bipolar manic (11.2%), bipolar depressed (10.5%), unipolar depressed (5.9%). The most frequent hallucinations across all patients were auditory, followed by somatic and visual hallucinations. There were only minor age or sex differences in risk of hallucinations. Compared with patients diagnosed with schizophrenia, hallucinations among patients with BPD were less severe, more visual and less often auditory. Characteristics of hallucinations were similar among manic and both bipolar- and unipolar-depressed subjects. Among patients with major affective disorders, those with hallucinations were less well-educated, had higher anxiety scores, less insight into the illness, and their hospitalizations averaged 17% longer. Across all diagnoses, hallucinations, particularly olfactory, were significantly associated with delusions. Hallucinations in BPD were most often accompanied by persecutory delusions; delusions of grandeur were least associated with hallucinations.

Conclusions

This study provides detailed descriptive data regarding the frequency (cross-sectional) and characteristics of hallucinations in a large sample of patients with BPD, major depression or schizophrenia. Our results suggest a link of lower education and the presence of hallucinations in major affective disorders. The significance of this finding, as well as the role of anxiety in hallucinating patients, requires further study.

---

### The ASAM clinical practice guideline on alcohol withdrawal management [^1153FUGG]. Journal of Addiction Medicine (2020). High credibility.

Recommendation I.11 — delirium in alcohol withdrawal — directs clinicians to conduct a detailed neurological and medical examination with appropriate testing to rule out other common causes of delirium regardless of the apparent etiology and to attempt to distinguish between hallucinations associated with alcohol withdrawal delirium and alcohol hallucinosis/alcohol-induced psychotic disorder. Patients presenting with delirium should be provided a neurological exam and medical evaluation to determine etiology, and the history and examination should provide a clear understanding of the relationship between cessation or reduction of alcohol intake and the onset of withdrawal signs and symptoms. The onset of alcohol withdrawal delirium typically occurs 24–48 hours after cessation of (or reduction in) alcohol use but can develop as many as 3–5 days later, and if a patient's alcohol use history and the time course of delirium are inconsistent or other causes are suspected, further testing should be completed to determine etiology.

---

### Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study [^114Q5e3b]. Neurology (2010). Low credibility.

Objective

To assess prospectively progression and relationship of hallucinations and sleep disorders over a 10-year longitudinal study of patients with Parkinson disease (PD).

Methods

Eighty-nine patients with PD were recruited to fill cells of normal sleep without hallucinations (n = 20), sleep fragmentation only (n = 20), vivid dreams/nightmares (n = 20), hallucinations with insight (n = 20), and hallucinations without insight (n = 9). At baseline, 0.5, 1.5, 4, 6, and 10 years, sleep disorders and hallucinations were assessed by standardized scales with the longitudinal data analyzed by generalized estimating equations with assumptions of linearity in time.

Results

At 10 years, we could account for all subjects (27 interviewed, 61 deceased, and 1 too ill for interview). Hallucination prevalence and severity increased over time (p < 0.0001, p = 0.0001). Acting out dreams also increased over time (p = 0.001). In contrast, presence of vivid dreams/nightmares or sleep fragmentation did not increase over time. For all visits, the prevalence of sleep fragmentation did not differ between subjects with vs without hallucinations (odds ratio [OR] = 1.50, p = 0.09). However, severe sleep fragmentation was associated with concurrent hallucinations (OR 2.01, p = 0.006). The presence of hallucinations was also highly associated with concurrent vivid dreams/nightmares (OR = 2.60, p < 0.0001) and with concurrent acting out dreams (OR = 2.38, p = 0.0004). Among the baseline nonhallucinators, no sleep abnormalities at study entry predicted future development of hallucinations.

Conclusions

Hallucinations and sleep abnormalities follow very different patterns of progression in PD over 10 years. Whereas patients with hallucinations often have concurrent sleep aberrations, no sleep problem is predictive of future hallucinations.

---

### Visual hallucinations: differential diagnosis and treatment [^116Rz9XX]. Primary Care Companion to the Journal of Clinical Psychiatry (2009). Low credibility.

Among other possible causes, visual hallucinations can be caused by substance-induced psychosis, bipolar disorder, delirium, Creutzfeldt-Jakob disease, schizophrenia, schizoaffective disorder, temporal lobe epilepsy, dementia with Lewy bodies, charles Bonnet syndrome, Parkinson's disease, recreational drug use, alcohol withdrawal syndrome, migraine with aura, brain tumors, brain metastasis, sleep deprivation, narcolepsy, posttraumatic stress disorder, depression, encephalitis, Wernicke's encephalopathy, hyponatremia, hypoglycemia and hallucinogen persisting perception disorder. In addition, visual hallucinations can be caused by medications such as tizanidine, benztropine, bromocriptine, moexipril, sulindac, benzonatate, lamotrigine, prucalopride and lamotrigine XR.

---

### Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a report of the AAN guideline subcommittee [^117RYmMu]. Neurology (2021). High credibility.

Prescribing dopamine agonists (DAs) in early Parkinson disease — before prescribing, clinicians should inform the patient and caregiver of important side effects of DAs, specifically including ICDs, EDS, sudden-onset sleep, nausea, postural hypotension, and hallucinations (Level B); should screen patients for cognitive impairment, EDS, sudden-onset sleep, hallucinations, orthostatic hypotension, and risk factors for ICDs before prescribing a DA (Level B); should screen repeatedly in follow-up for DA-related adverse effects including ICDs, EDS, sudden-onset sleep, orthostatic hypotension, cognitive impairment, and hallucinations (Level B); and should involve caregivers in these assessments (Level B). Rationale notes that DAs vs levodopa are associated with increased risk of ICDs, EDS, sudden-onset sleep, nausea, and hallucinations in early PD, and may exacerbate postural hypotension.

---

### Joint clinical practice guideline on benzodiazepine tapering: considerations when risks outweigh benefits [^1171Trqv]. Journal of General Internal Medicine (2025). High credibility.

Protracted withdrawal symptom profile — Protracted withdrawal symptoms may include but are not limited to psychological symptoms such as anxiety, depression, agitation, anhedonia, and hallucinations; neurological symptoms such as poor memory and cognition, distractedness, formication, paresthesia, and tinnitus; neuropsychiatric symptoms including akathisia and psychosis; and other symptoms including motor disturbances, gastrointestinal disturbances, insomnia, and dizziness.

---

### Hallucinations in parkinson disease [^113bnmpL]. Nature Reviews: Neurology (2009). Medium credibility.

Patients with Parkinson disease (PD) can experience hallucinations (spontaneous aberrant perceptions) and illusions (misinterpretations of real perceptual stimuli). Of such phenomena, visual hallucinations (VHs) and illusions are the most frequently encountered, although auditory, olfactory and tactile hallucinations can also occur. In cross-sectional studies, VHs occur in approximately one-third of patients, but up to three-quarters of patients might develop VHs during a 20-year period. Hallucinations can have substantial psychosocial effects and, historically, were the main reason for placing patients in nursing homes. Concomitant or overlapping mechanisms are probably active during VHs, and these include the following: central dopaminergic overactivity and an imbalance with cholinergic neurotransmission; dysfunction of the visual pathways, including specific PD-associated retinopathy and functional alterations of the extrastriate visual pathways; alterations of brainstem sleep-wake and dream regulation; and impaired attentional focus. Possible treatments include patient-initiated coping strategies, a reduction of antiparkinson medications, atypical neuroleptics and, potentially, cholinesterase inhibitors. Evidence-based studies, however, only support the use of one atypical neuroleptic, clozapine, and only in patients without dementia. Better phenomenological discrimination, combined with neuroimaging tools, should refine therapeutic options and improve prognosis. The aim of this Review is to present epidemiological, phenomenological, pathophysiological and therapeutic aspects of hallucinations in PD.

---

### Sleep duration and psychotic experiences in patients at risk of psychosis: a secondary analysis of the EDIE-2 trial [^1158DWMs]. Schizophrenia Research (2019). Medium credibility.

Sleep disturbance is common among individuals at risk of psychosis, yet few studies have investigated the relationship between sleep disturbance and clinical trajectory. The Early Detection and Intervention Evaluation (EDIE-2) trial provides longitudinal data on sleep duration and individual psychotic experiences from a cohort of individuals at risk of psychosis, which this study utilises in an opportunistic secondary analysis. Shorter and more variable sleep was hypothesised to be associated with more severe psychotic experiences and lower psychological wellbeing. Mixed effect models were used to test sleep duration and range as predictors of individual psychotic experiences and psychological wellbeing over the 12–24 months (with assessments every 3 months) in 160 participants. Shorter sleep duration was associated with more severe delusional ideas and hallucinations cross-sectionally and longitudinally. The longitudinal relationships did not remain significant after conservative controls were added for the previous severity of psychotic experiences. No significant relationships were found between the sleep variables and other psychotic experiences (e.g. cognitive disorganisation), or psychological wellbeing. The results support a relationship between shorter sleep duration and delusional ideas and hallucinations. Future studies should focus on improving sleep disturbance measurement, and test whether treating sleep improves clinical trajectory in the at-risk group.

---

### Pharmacological and somatic treatments for first-episode psychosis and schizophrenia: synopsis of the US department of veterans affairs and US department of defense clinical practice guidelines [^113G1mc4]. Schizophrenia Bulletin (2025). High credibility.

Early warning signs of psychosis — changes that suggest possible delusions, hallucinations, disorganization, functional impairments, unexplained deteriorations in performance, cognition, or both — include: Worrisome drop in grades or job performance; New trouble thinking clearly or concentrating; Suspiciousness, paranoid ideas, or uneasiness with others; Social withdrawal or more time spent alone than usual; Unusual, overly intense new ideas, strange feelings, or no feelings at all; Decline in self-care or personal hygiene; Difficulty telling reality from fantasy; and Confused speech or trouble communicating.

---

### From tones in tinnitus to sensed social interaction in schizophrenia: how understanding cortical organization can inform the study of hallucinations and psychosis [^114SSGDa]. Schizophrenia Bulletin (2014). Low credibility.

Introduction

Brain imaging has made substantial contributions to our understanding of hallucinations. One advance has been in the characterization of brain changes that predispose an individual to having hallucinations (hallucination trait); these have helped delineate structural and functional changes in brain networks of those at risk of hallucinations in schizophrenia, Parkinson's disease, and the dementias (see Allen et aland ffytchefor reviews). Our focus here is on a different aspect of hallucination neurobiology, the activity captured at the time of a hallucination (hallucinating state) and its relationship to hallucination content, a domain of psychopathology that has received little research attention in the modern era. The identification of cortical regions activated during a hallucination helps categorize the experience in terms of its relationship to memory, perception, imagery, emotional circuitry, and better understand the consequences of trait changes in brain networks. However, our ambition goes beyond this in an attempt to fully explain the content of hallucinated experience in terms of the underlying cortical regions. By matching the location of activation foci during hallucinations to regions with putative homology to those identified in nonhuman primate studies of neurophysiological properties at the single cell or neuronal population level, it is apparent that hallucination content and cortical specialization are directly related. For simple visual and auditory experiences at least, evidence is emerging that the content of a hallucination is defined by the single cell and population properties of cells activated at the time of the hallucination. Put another way, the phenomenological content (or qualia) of hallucinated perceptual experience is linked to the neurobiology of cortex activated at the time of the hallucination.

---

### Hallucinations and sleep disorders in PD: six-year prospective longitudinal study [^111ui6Ab]. Neurology (2005). Low credibility.

Objective

To prospectively assess the relationship of hallucinations to sleep disorders in patients with Parkinson disease (PD) over 6 years.

Background

Several studies suggest an association between hallucinations and sleep disruption, but no longitudinal study has examined their progression and relationship, nor whether sleep alterations predict future hallucinations.

Methods

Eighty-nine PD patients were recruited to fill cells of normal sleep without hallucinations (n = 20); sleep fragmentation only (n = 20); vivid dreams/nightmares (n = 20); hallucinations with insight (n = 20); hallucinations without insight (n = 9). At baseline, 6 months, 18 months, 4 years, and 6 years, sleep disorders and hallucinations were assessed by standardized scales with the longitudinal data analyzed by generalized estimating equations and other nonparametric tests.

Results

At 6 years, we could account for all subjects (49 interviewed, 40 deceased or too ill for interview). Hallucination prevalence and severity increased over time (p < 0.0001). The odds of being a hallucinator increased by a factor of 1.39 at each successive time point. Sleep disorders, however, fluctuated widely among patients and time points, with no evidence of progression in severity (p = 0.73). The prevalence of sleep fragmentation did not differ between subjects with vs without hallucinations (OR = 1.43, p = 0.13). The presence of vivid dreams/nightmares, however, was highly correlated with the concurrent presence (OR = 2.32) and severity of hallucinations (OR = 3.02, both p < 0.0001). Vivid dreams/nightmares among non-hallucinators did not predict future development of hallucinations (OR = 0.94, p = 0.51).

Conclusions

Hallucinations and global sleep disorders follow different patterns of progression in Parkinson disease and are separate behavioral abnormalities. Sleep alterations are not necessarily harbingers of hallucinations.

---

### American psychiatric association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. second edition [^112ri5SK]. The American Journal of Psychiatry (2007). Medium credibility.

Dementia with Lewy bodies — clinical features, cautions, and frequency: Dementia with Lewy bodies has been recognized clinically only in the last 10–15 years and differs from Alzheimer's disease by earlier, more prominent visual hallucinations, early parkinsonian features (postural instability and falls), cognitive fluctuations lasting days to weeks, and a somewhat more rapid evolution. Patients are markedly sensitive to the extrapyramidal effects of antipsychotic medications, and these medications should be used only with the utmost caution. Lewy bodies may account for as many as 7%–26% of dementia cases, depending on the criteria used. The neuropathology of Parkinson's disease and dementia with Lewy bodies are interrelated with an abundance of Lewy inclusion bodies in both subcortical and cortical regions; autopsy often reveals both dementia with Lewy bodies and Alzheimer's disease, creating controversy about their independence, and development of valid clinical and pathological diagnostic criteria is an area of active research.

---

### Visual hallucinations in Parkinson's disease: a review and phenomenological survey [^116Nfbp4]. Journal of Neurology, Neurosurgery, and Psychiatry (2001). Low credibility.

Objectives

Between 8% and 40% of patients with Parkinson's disease undergoing long term treatment will have visual hallucinations during the course of their illness. There were two main objectives: firstly, to review the literature on Parkinson's disease and summarise those factors most often associated with hallucinations; secondly, to carry out a clinical comparison of ambulant patients with Parkinson's disease with and without visual hallucinations, and provide a detailed phenomenological analysis of the hallucinations.

Methods

A systematic literature search using standard electronic databases of published surveys and case-control studies was undertaken. In parallel, a two stage questionnaire survey was carried out based on members of a local branch of the Parkinson's Disease Society and followed up with a clinical interview.

Results

The review disclosed common factors associated with visual hallucinations in Parkinson's disease including greater age and duration of illness, cognitive impairment, and depression and sleep disturbances. The survey comprised 21 patients with visual hallucinations and 23 without. The hallucinators had a longer duration and a greater severity of illness, and tended to show more depressed mood and cognitive impairment. The typical visual hallucination in these patients is a complex visual image experienced while they are alert and have their eyes open. The image appears without any known trigger or voluntary effort, is somewhat blurred, and commonly moves. It stays present for a period of "seconds" or "minutes". The content can be variable within and between hallucinators, and includes such entities as people, animals, buildings, or scenery. These features resemble those highlighted in hallucinations in the visually impaired (Charles Bonnet's syndrome).

Conclusion

A consistent set of factors are associated with visual hallucinations in Parkinson's disease. The results of the phenomenological survey and those of visual hallucinations carried out in other settings suggest a common physiological substrate for visual hallucinations but with cognitive factors playing an as yet unspecified role.

---

### Pseudohallucinations: a pseudoconcept? A review of the validity of the concept, related to associate symptomatology [^116Tz882]. Comprehensive Psychiatry (2001). Low credibility.

"Pseudohallucination" is a concept used in the classification of nonpsychotic perceptual disorders. This report describes the history of the concept and investigates whether pseudohallucinations can be differentiated from related psychopathological symptoms, such as hallucinations, re-experiencing, and dissociative phenomena. We performed a literature review, which shows that pseudohallucinations and related symptoms have low construct validity and are, accordingly, clinically ambiguous. Most likely, pseudohallucinations are placed on an overlapping continuum of symptomatology that includes perceptual disorders, re-experiencing, (dissociative) imagery, and normal thought and memory processes. Recommendations are made regarding the specification of dimensions of this continuum. The term "nonpsychotic hallucinations" is preferred over "pseudohallucination".

---

### Towards an integrative account of potential mechanisms mediating the path from sleep dysfunction to hallucinations [^113jDDVD]. Schizophrenia Bulletin (2025). Medium credibility.

Lived experience accounts highlight the importance of cognitive processes in deciding whether to rely on what a voice is saying. This is described as an intentional process and involves holding in mind multiple pieces of relevant information and inhibiting irrelevant information in order to reach a decision about the veracity and source of the perceptual experience (a voice vs external source). The process is likely supported by working memory, inhibitory control, and source monitoring processes. Intentional cognitive inhibition refers to the ability to consciously and deliberately suppress non-relevant material from working memory. A lab-based sleep deprivation study found that false alarms on an intentional inhibition task increased following 24-hours of wakefulness, and decreased after a recovery sleep. Separately, a number of studies have shown that people reporting hallucinatory experiences make more false alarm responses on an inhibitory control task (ie, fail to suppress irrelevant stimuli) than non-hallucinating participants. Testing the full mechanistic path from sleep disruption to hallucinations via inhibitory control is a clear area for further research. The role of working memory in the sleep-hallucinations relationship has been experimentally tested in general population groups, confirming that sleep loss impairs working memory;, however, there was no support for a mediating role of working memory in the effect of sleep loss on the occurrence of hallucinatory experiences. The relationship from sleep disruption to believing negative voice content, via working memory, has not been assessed.

---

### Longitudinal thalamic white and Grey matter changes associated with visual hallucinations in Parkinson's disease [^1159KSDj]. Journal of Neurology, Neurosurgery, and Psychiatry (2022). Medium credibility.

Objective

Visual hallucinations are common in Parkinson's disease (PD) and associated with worse outcomes. Large-scale network imbalance is seen in PD-associated hallucinations, but mechanisms remain unclear. As the thalamus is critical in controlling cortical networks, structural thalamic changes could underlie network dysfunction in PD hallucinations.

Methods

We used whole-brain fixel-based analysis and cortical thickness measures to examine longitudinal white and grey matter changes in 76 patients with PD (15 hallucinators, 61 non-hallucinators) and 26 controls at baseline, and after 18 months. We compared white matter and cortical thickness, adjusting for age, gender, time-between-scans and intracranial volume. To assess thalamic changes, we extracted volumes for 50 thalamic subnuclei (25 each hemisphere) and mean fibre cross-section (FC) for white matter tracts originating in each subnucleus and examined longitudinal change in PD-hallucinators versus non-hallucinators.

Results

PD hallucinators showed white matter changes within the corpus callosum at baseline and extensive posterior tract involvement over time. Less extensive cortical thickness changes were only seen after follow-up. White matter connections from the right medial mediodorsal magnocellular thalamic nucleus showed reduced FC in PD hallucinators at baseline followed by volume reductions longitudinally. After follow-up, almost all thalamic subnuclei showed tract losses in PD hallucinators compared with non-hallucinators.

Interpretation

PD hallucinators show white matter loss particularly in posterior connections and in thalamic nuclei, over time with relatively preserved cortical thickness. The right medial mediodorsal thalamic nucleus shows both connectivity and volume loss in PD hallucinations. Our findings provide mechanistic insights into the drivers of network imbalance in PD hallucinations and potential therapeutic targets.

---

### Musical hallucinations: prevalence in psychotic and nonpsychotic outpatients [^115bA9sE]. The Journal of Clinical Psychiatry (2004). Low credibility.

Background

Musical hallucinations have been considered a rare manifestation of psychotic states or brain and hearing abnormalities. However, an obsessive-compulsive disorder (OCD) assessment tool refers to musical hallucinations and our preliminary study showed that about one third of OCD patients experienced musical hallucinations.

Aims

To elucidate the lifetime prevalence of musical hallucinations among psychotic and nonpsychotic psychiatric outpatients.

Methods

Lifetime experience of musical hallucinations was examined with a specially designed structured interview in 190 consecutive outpatients with diagnoses of anxiety, affective, and schizophrenia disorders.

Results

Musical hallucinations occurred in more than one fifth of all diagnoses. The prevalence of musical hallucinations was highest in OCD patients (41%). Musical hallucinations were significantly more frequent with more comorbid disorders, and logistic regression revealed that this finding was mainly due to OCD combined with either social phobia or schizophrenia.

Conclusion

Musical hallucinations are more common among psychiatric patients than previously reported and are more suggestive of OCD than of other mental disorders.

---

### Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial [^111aDuJL]. The Lancet: Psychiatry (2015). Medium credibility.

The clear caution when discussing potential clinical effects is that this study was a pilot study. Our trial is insufficiently powered to detect anything but the largest effect sizes. There was no formal power calculation because we did not primarily intend to detect treatment effects. We did not achieve the target sample size of 60 patients, but this information will form part of the recruitment strategy plan for the future phase 3 trial. Our main purpose was to assess the feasibility of the assessment and to refine procedures. A key observation was the wide variety of sleep disturbance within the patient group, including patients going to bed early in the evening and simply lying awake for hours, patients not having a bed, patients having an association with their bed as a place of trauma, patients awake and pacing all night, patients' sleep being disturbed through the use of hypnotics, patients being drowsy and oversleeping at various times of the day, and patients only going to bed in the early hours (delayed-phase sleep), whereas others had obviously irregular sleep–wake patterns. Our treatment manual will become more specific to each of these types of presentation and it would be of interest to establish whether they are associated with different outcomes. Such presentations are consistent with evidence of varied circadian rhythm dysfunction in patients with schizophreniaand, indeed, the complexity of sleep disturbance beyond insomnia in other disorders such as bipolar disorder. Notably, our trial did not include polysomnography. Obvious practical difficulties exist in implementation of such a measurement, and subjective reports of problems must be the key clinical priority. Instead of polysomnography we used actigraphy to assess sleep–wake timing and fragmentation. This form of assessment (wearing a watch-like device) was not agreed to by all participants. Furthermore, we have concerns that the movement recordings are not able to differentiate between actual sleep and drowsy but awake inactivity, which is common in this patient group. Such recordings might be better used to assess changes in overall activity levels, which is an important outcome in itself. Sleep improvement might also lead to physical health benefits.

---

### Collaborative care in the identification and management of psychosis in adolescents and young adults [^1154p1aF]. Pediatrics (2021). High credibility.

Psychosis in adolescents and young adults — physical examination: When a patient presents with psychotic-like symptoms, providers should perform a thorough physical examination with a detailed neurologic examination to exclude medical etiologies, and focal neurologic findings may warrant urgent consultation with neurology and may require additional evaluation such as EEG and brain imaging. Hallucinations that are primarily gustatory or olfactory can be suggestive of organic causes, although a more recent study suggests tactile, olfactory, and gustatory hallucinations are actually common in primary psychotic disorders and not necessarily indicative of organic brain disease. Hallucinations associated with headaches warrant referral to a neurologist as well.

---

### Musical hallucinations in normal children and adult non-psychiatric population [^1146waDW]. BMJ Case Reports (2009). Medium credibility.

A descriptive account of musical hallucinations of a series of 19 people is presented. Five people reported the onset of hallucination before adulthood. In this paper we demonstrate that musical hallucinations are not necessarily pathological and can occur as a normal experience in people (children and adults) who have no contact with mental health services and no concurrent mental disorder. This is also the first paper to recognise that children can experience musical hallucinations. Also, we show that musical hallucinations are more common than previously thought, but people do not report their occurrence. It seems plausible that in musical hallucinations there is an insult to the ear or brain that produces a change in quality of these images, converting them to a psychotic experience. Musical hallucinations should be regarded as a continuum with normal experiences and clinical syndromes.

---

### Auditory hallucinations induced by trazodone [^1171n8rv]. BMJ Case Reports (2014). Medium credibility.

A 26-year-old female outpatient presenting with a depressive state suffered from auditory hallucinations at night. Her auditory hallucinations did not respond to blonanserin or paliperidone, but partially responded to risperidone. In view of the possibility that her auditory hallucinations began after starting trazodone, trazodone was discontinued, leading to a complete resolution of her auditory hallucinations. Furthermore, even after risperidone was decreased and discontinued, her auditory hallucinations did not recur. These findings suggest that trazodone may induce auditory hallucinations in some susceptible patients.

---

### Guidelines for managing substance withdrawal in jails [^1162VBaE]. BJA/NIC (2023). High credibility.

ASAM/AAAP psychosis definition — psychosis is an abnormal mental state involving significant problems with reality testing; characterized by serious impairments or disruptions in the most fundamental higher brain functions — perception, cognition and cognitive processing, and emotions or affect — as manifested in behavioral phenomena, such as delusions, hallucinations, and significantly disorganized speech.